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Tissue engineered bone grafts could potentially revolutionize treatments for massive 
bone defects, offering greater tissue quantities and graft customization over the gold 
standard autograft. However, scale-up of cell-seeded grafts requires rapid vascularization in 
order to maintain high cell viability and function after implantation. Engineering vasculature 
inside the graft may greatly accelerate blood perfusion of the whole tissue, rather than relying 
solely on slow angiogenic ingrowth. Development of a complex tissue graft poses several 
challenges, including the concurrent stimulation of two lineages, as well as the selection of 
clinically relevant cell source(s). Therefore, the objective of this thesis was to develop a 
protocol to engineer vascularized bone grafts with a single, clinically relevant cell source: 
adipose-derived stem cells (ASCs). ASCs can be harvested autologously via liposuction with 
very high yield and are unique in that they have both osteogenic and vascular potential, 
making them a promising cell source to supply key components of a vascularized bone graft. 
 This body of work describes a multistep approach towards the aforementioned objective. 
First, the potential of ASCs to form functional vasculature networks was explored. By 
increasing the direct physical interactions amongst cells, it was demonstrated that small 
lingering sub-populations of vascular cells are capable of spontaneously proliferating and 
self-assembling into three-dimensional pericyte-stabilized vascular networks. The next two 
chapters describe the development of a step-wise in vitro protocol to induce vascularized 
bone by recapitulating the biochemical environment of native bone repair. This study 
highlighted factors derived from platelets and inflammatory cells that promote vascular 
growth and stability, as well as osteogenic mineralization.  Lastly, the effects of hypoxia on 
vascular assembly and stability were studied to understand how ASC-seeded grafts may 
iii 
 
behave in an ischemic bone injury environment. This investigation revealed that hypoxia 
severely inhibits de novo vascular assembly, but promotes growth and stability of pre-formed 
vessels. Taken together, these findings have significant implications for how ASCs could be 
applied clinically for bone regeneration. 
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Chapter 1  
Introduction 
1.1 Critical-Size Bone Defects 
Bone is a highly regenerative tissue that has considerable potential to fully heal itself 
following traumatic injury. However, when the size of the defect is beyond a critical healing 
threshold (approximately a few centimeters in humans), normal healing cascades are 
disrupted (Fig. 1.1), and the defect may never completely heal. These defects are termed 
‘critical-size’ and may be due to trauma, congenital defects, or disease. Complicating factors 
that can impede healing include missing critical sources of regenerative cues (i.e. periosteum, 
hematoma) and may be prone to mechanical / structural instability and infection [1]. Bone 
grafting is often required to facilitate healing of these defects. 
More than one million Americans each year require bone grafts for the regeneration of 
critical-size bone defects, with an economic burden in excess of $1B annually [2]. The gold 
standard for treatment is autologous bone grafts, which are often harvested from the iliac 
crest, fibula, or ribs. Autografts contain viable bone cells and osteoinductive factors, which 
facilitate rapid osteogenesis and remodeling at the site of transplant. However, the limited 
availability of autografts and donor site complications pose challenges for their use [3]. 
Allogeneic bone grafts and synthetic grafting materials (e.g. tricalcium phosphate) are more 
abundant alternatives that have osteoinductive and osteoconductive properties, but require 





Figure 1.1. Normal bone healing and its coupling with vascularization. (A) Vascular damage 
occurs concomitantly with bone fracture, resulting in local bleeding that clots to form a hematoma. 
An acute inflammatory phase begins immediately, wherein white blood cells (WBCs) secrete pro-
inflammatory cytokines and degranulating platelets release growth factors. These inflammatory 
factors signal the recruitment and proliferation of osteoprogenitor cells (OPs) from the periosteum, 
bone marrow, muscle, and/or perivascular position. The periosteum not only serves as a major 
source of OPs and vasculature, but also structural support (if still in tact). (B) Over the course of a 
few weeks, the hematoma is resorbed and replaced by granulation tissue, followed by 
fibrocartilagenous tissue (‘soft callus’). Lack of blood flow within the defect results in hypoxia, which 
causes an increase in expression of VEGF by OPs. Invading endothelial cells (ECs) respond to 
VEGF gradients via increased angiogenesis into the defect site. These ECs express BMP-2, which 
induces differentiation of OPs into osteoblasts (OB). (C) After a few weeks, the callus becomes 
mineralized into woven bone (‘hard callus’) that completely bridges the defect (i.e. union). During 
this regeneration phase, growing vessels secrete PDGF-B to recruit pericytes (PCs) who secrete 
factors that help stabilize and mature the vessels (e.g. Ang-1). These vessels pattern the newly 
forming bone trabeculae, as OBs orient around the vessel and begin secreting osteoid 
outward. (D) Long-term remodeling via osteoclasts (OCL) and OBs transforms the hard callus into 
ordered lamellar bone. Osteocytes orient in circumferential lamellae around blood vessels. 
1.2 Cell Transplantation & Vascularization 
Bone tissue engineering is a promising alternative that allows the combination of 
supportive scaffolds, regenerative cells, and inductive cues to recapitulate the normal fracture 




significantly improve bone healing over acellular grafts [4-6] and has been employed 
clinically in a small number of cases [7-9]. However, its adoption into clinical practice has 
been limited by issues regarding reproducibility, efficacy, cost-effectiveness, and safety [10]. 
Vascularization of tissue-engineered grafts is critical to the survival and efficacy of 
transplanted cells to ensure adequate delivery of oxygen and nutrients. The vascular damage 
that occurs with bone injury renders sites of large bone defects highly ischemic. Delivering 
cells to the defect site further increases the local metabolic demand and exacerbates the 
detrimental effects arising form the lack of adequate oxygen supply. Vascularization of an 
implant that is several centimeters in size may take weeks. Therefore, encouraging vascular 
growth within cell-seeded grafts has become an important topic of research. 
1.3 Approaches to Engineer Vascularized Bone 
Several approaches have been developed to vascularize an engineered bone graft, 
including engineering vasculature before implantation, as well as encouraging vascular 
growth in vivo (Fig. 1.2). Engineering vascular networks within grafts prior to implantation 
(termed “pre-vascularization”) may accelerate the rate of blood perfusion if they can quickly 
fuse (“anastomose”) with established vasculature in surrounding tissues (Fig. 1.2 top). 
Several studies have shown this is possible [11-13], with a more recent study shedding light 
on the novel ‘wrapping and tapping’ mechanism by which engineered vessels anastomose 
with host vessels [14]. With this in mind, numerous approaches to engineer vascularized 
bone have implemented an in vitro pre-vascularization strategy [15] in order to maintain high 
cell viability during the vascularization process as well as greater control over the 




[16], establishing in vitro cultivation protocols that enable robust, synergistic development of 
both bone and vasculature has remained a persistent challenge since the biochemical cues 
that are present in the culture medium to stimulate bone development impede vascular 
growth and vice-versa [17-20]. Therefore, to develop tissue grafts that have both vascular 
and mineral components, groups have primarily either (i) utilized staged-induction 
approaches where angiogenic factors are provided for a period to stimulate vessel formation 
prior to introducing osteogenic supplements [17, 21-23] or (ii) cultured cells separately in 
medium optimized for vessel formation or osteogenic differentiation prior to recombining 
the various cell populations in a single tissue graft [24-27]. Additional studies have utilized 
perfusion or rotating-wall bioreactors to increase transport of oxygen and nutrients, as well 
as provide mechanical cues via shear stress, which increases tissue formation [28-30]. Further 
studies are required to understand how bioreactor culture affects vascularized bone 
development, as the direct effects on vasculature remain unclear. In addition, extensive 
and/or complex in vitro cultivation methods may not be readily adopted in the clinic in the 
near future due to logistical, regulatory, and financial hurdles. 
Rather than pre-culture vasculature in vitro, it is possible to utilize the body itself as an in 
vivo ‘bioreactor’ to pre-vascularize the scaffold in an ectopic site (Fig. 1.2 middle). This two-
step procedure involves implanting a scaffold within a highly vascularized bed, such as 
muscle or within an arteriovenous (AV) loop, for several weeks until extensive vascular 
networks have penetrated the graft. This scaffold can then be transplanted as a free flap to 
the orthotopic site with surgical anastomosis of major vessels to immediately perfuse the 
graft with blood [31, 32]. Clinically, there have been a few successful cases of ectopic pre-




aspirate or ASCs have been combined with osteoinductive cues within titanium mesh cages, 
then implanted within muscle tissues to vascularize [7, 9]. Grafts were subsequently 
transplanted to defect sites. While partially successful, complications related to infections and 
necrosis ultimately occurred [33].  
 To enhance clinical applicability, it may be advantageous to seed a scaffold with cells and 
immediately implant into the defect site for in situ tissue formation (Fig. 1.2 bottom). 
However once in vivo, it is much more difficult to control the graft microenvironment. 
Successful regeneration may require tight control over the delivery of inductive cues to guide 
robust formation of perfusable vascular networks surrounded by mature, organized bone. 
 
Figure 1.2. Vascularization approaches for bone tissue engineering. (TOP) In vitro pre-
vascularization techniques induce cell-seeded scaffolds to form vasculature with exogenous growth 
factors. (MIDDLE) In vivo ectopic pre-vascularization involves implantation of a cell-seeded scaffold 
into a highly vascularized bed to allow angiogenic ingrowth before free flap transplantation with 
surgical anastomosis. (BOTTOM) In vivo orthotopic vascularization involves direct implantation of 
scaffolds into the bone defect for in situ tissue development. Scaffolds can be functionalized for the 





1.4 Clinically Relevant Cell Sources 
Numerous autologous stem / progenitor cell sources have been utilized in bone tissue 
engineering research (Table 1.1), often involving mesenchymal stem cells (MSCs) from bone 
marrow or adipose tissue because of their osteogenic potential. Adipose-derived stem cells 
(ASCs) are particularly attractive for clinical application because their multipotency, 
abundance, and ease of harvest via liposuction. 
Table 1.1. Autologous stem / progenitor cell sources for engineering vascularized bone. 
Cell Population Advantages Disadvantages 
Minimally Processed Tissue Sources 
Bone Marrow 
(BM) 
• Osteoinductive properties (e.g. bone 
chips in reamed / ‘enhanced’ BM) 
• Endothelial sub-population 
• Intraoperative use 
• Limited tissue availability 
• Composition will vary amongst donors 




• Abundant tissue 
• Easily harvested via liposuction 
• High proportion of stem cells and 
endothelial cells 
• Intraoperative use 
• Cell population varies amongst donors 
and isolation procedures 
• 2 – 3 hour multi-step isolation 
procedure 
 
Isolated Adult Stem / Progenitor Cells 
Mesenchymal 
Stem Cells from 
BM (BM-MSC) 
• Osteogenic potential 
• Studied extensively 
• Very low yield from BM, requiring 
extensive in vitro expansion 
• Requires addition of endothelial cells 
to form vessels 
Adipose-Derived 
Stem Cells (ASC) 
• Osteogenic potential 
• High yield from adipose tissue 
• Vascular  potential 





• Autologous endothelial source 
• Non-invasively harvested from blood 
• Capable of maturation into functional 
vascular networks 
• Very low yield, requiring extensive in 
vitro expansion 
• Not capable of forming bone 




• Autologous pluripotent cells  
• Capable of differentiating into all cell 
types in bone 
• Reprogramming efficiency very low, 
requiring extensive expansion 
• Safety concerns, limited clinical 
application 
 
Adipose tissue is primarily composed of adipocytes and pre-adipocytes. The remaining 




40 million cells per 100 milliliters of adipose tissue. SVF contains mesenchymal stem cells 
(ASCs, ~25-50%), endothelial cells (ECs, ~15-30%), pericytes (2-5%), and immune / 
hematopoietic lineage cells (~20-30%) [34-36]. After culturing and serial passaging SVF, the 
majority of the endothelial and hematopoietic lineage cells are lost, either because of non-
adherence, slow proliferation, or death. This results in a seemingly pure population of ASCs 
by passage 2 or 3 [35]. 
Co-culture of stem cells with an EC source, such as endothelial progenitor cells or 
mature ECs, has demonstrated promise in promoting bone vascularization in vitro and in vivo 
[15, 37-39]. However, the separate harvest, purification, and expansion of additional cell 
types complicate these approaches. Yet, ASCs may not require co-culture, as they have been 
reported to give rise to both endothelial [40-42] and perivascular cells [43-47], each of which 
is essential to form mature, stabilized vessels [48, 49]. However, prior to these studies the 
ability of ASCs to form vascular networks was debated and poorly understood. Therefore, 
this thesis first explores the vascular properties of these cells, and then demonstrates that 
they can be utilized as a single, clinically relevant cell source to give rise to both osteogenic 
and vascular components of a complex tissue graft. 
1.5 Specific Aims 
The overall goal of this thesis was to elucidate the biochemical and biophysical cues that 
can induce ASCs to form robust vascularized bone. To accomplish this goal, initial studies 
determined if and how ASCs could form 3D vascular networks. After setting this 
groundwork, a protocol was developed to induce the co-development of both vasculature 




environment. Lastly, the effects of hypoxia on ASC vascularization were investigated to 
simulate the challenging hypoxic environment of a bone defect. These studies are 
summarized by three Specific Aims: 
 
Aim 1. Induce functional assembly of vascular networks by ASCs (Chapter 2) 
1.1. Understanding the vascular potential of ASCs 
1.2. Spatial organization of cells 
Aim 2. Develop an induction protocol to engineer robust vascularized bone by 
recapitulating factors in native bone repair (Chapter 3-4) 
2.1. PDGF-BB 
2.2. Inflammatory cytokines 
Aim 3. Evaluate the effects of hypoxia on ASC viability and vascularization (Chapter 5) 
3.1. De novo vascular assembly 




Chapter 2  
Vascular Morphogenesis: Major Role of 
a Minority Endothelial Sub-Population 
2.1 Introduction and Background 
 Heterogeneity in adipose-derived stromal/stem cell (ASC) cultures can give rise to novel 
cellular interactions that may be useful for regeneration of complex tissues comprised of 
multiple cellular phenotypes. Yet, the importance of cell population heterogeneity is an 
under-explored concept in tissue engineering. ASCs hold great promise as an autologous cell 
source for regenerative medicine due to their abundance, ease of harvest via liposuction, and 
multipotency [50]. In addition to their well-studied potential towards the classic 
mesenchymal lineages (bone, cartilage, fat) [51], ASCs possess vascular properties and can 
give rise to both endothelial [40-42] and perivascular cells [43-47]. Each of these populations 
is essential to form stable vascular networks [48, 49]. Therefore, the potential to supply all 
tissue components from a single autologous cell source would be a powerful tool in 
engineering complex vascularized grafts. 
 Several studies have investigated the perivascular and endothelial potentials of ASCs. 
Intriguingly, it has been demonstrated that ASCs may be resident in perivascular sites in 
native adipose tissues [46, 47]. They also possess the ability to secrete pro-angiogenic factors 




vascular networks is less clear.  Approaches towards in vitro endothelial differentiation are 
typically growth factor-mediated [40, 41, 55], and involve Matrigel [40, 56], hypoxia [57], 
shear stress [58, 59], or spontaneous transformation [42, 60]. All of these studies have 
reported successfully increasing the overall endothelial phenotype in cultures, though the 
functional characteristics of these cells and the phenotypes of the non-endothelial cells 
remain unclear.  There is also evidence that ASCs differentiate into endothelial cells in vivo 
and engraft into host vasculature [41, 42]. These studies have been counter-balanced by the 
assertion that ASCs inherently have limited endothelial potential due to epigenetic 
restrictions of endothelial gene promoters [61]. Each of these studies raises important 
questions regarding the robustness of the endothelial potential of ASCs and whether it is 
possible to simultaneously obtain endothelial and perivascular subpopulations within the 
same culture. 
These questions may be answered by studying their phenotypic profiles. ASCs are 
isolated from adipose tissue by selecting for the plastic-adherent population of the stromal 
vascular fraction (SVF) [62, 63]. These cells have been extensively characterized by multiple 
laboratories who have reported on their phenotypes across multiple donors [35, 41, 59], 
passages [35, 64], extraction methods [41, 65], and clonal differentiation potentials [66]. 
While they do exhibit increasingly homogenous profiles with sustained in vitro cultivation, 
demonstrating greater than 90% positive expression of mesenchymal surface markers CD13, 
CD29, CD73, and CD90 by passage 3 [35, 64], ASCs are still widely considered a 
heterogeneous population. There also often exists a minority subpopulation that expresses 
endothelial cell-associated markers, such as CD31. This CD31+ population can range 




with sustained in vitro cultivation.  More interestingly, this inherent heterogeneity might even 
be intentionally utilized to induce formation of complex tissue structures in engineered grafts. 
The current study aims to investigate the ability of ASCs to form stable vascular 
structures in vitro. By modulating the spatial organization of the cells in 2D culture (seeding 
density) and in 3D culture (multicellular aggregation), we demonstrated that multiple ASC 
subpopulations are able to closely interact and spontaneously self-assemble into three-
dimensional vascular structures. This report explores this phenomenon and elucidates the 
cellular behaviors that are necessary to generate stable vascular networks with ASCs. 
2.2 Materials and Methods 
ASC Isolation and Culture 
 ASCs were isolated at the Stem Cell Biology Laboratory, Pennington Biomedical 
Research Center, under an Institutional Review Board approved protocol according to 
published methods [67]. Briefly, fresh human subcutaneous adipose lipoaspirates were 
obtained under informed consent from five healthy Caucasian female donors undergoing 
elective liposuction surgery with a mean age of 47.6 ± 1.9 years and mean body mass index 
of 27.1 ± 0.6. Fat depots included (number of donors denoted): thighs (3), abdomen (2), 
hips and flanks (2). The lipoaspirate tissue was extensively washed with warm phosphate 
buffer solution to remove erythrocytes and then digested in PBS supplemented with 0.1% 
Collagenase Type I (Worthington Biochemical Corp.), 1% BSA, and 2 mM CaCl2 for one 
hour at 37 ºC. Following room temperature centrifugation at 300 g and resuspension in 
Stromal Medium (DMEM/Hams F-12 Medium supplemented with 10% FBS (Hyclone) and 




digest was plated in a T175 flask (0.2 ml per cm2). After 24 hrs of incubation at 37 ºC, 5% 
CO2, the adherent cells were washed with warm PBS and maintained in Stromal Medium 
until 80-90% confluent. The adherent population (“passage 0”) was harvested by digestion 
with trypsin (0.05%)/EDTA (1 mM) at 37 ºC for five minutes, washed with Stromal 
Medium and cryopreserved [68] for shipment to Johns Hopkins University. Prior studies 
have demonstrated no deleterious effects on ASCs due to cryopreservation, such as loss of 
viability or multipotency [68-70]. For expansion, ASCs were thawed and cultured in 
expansion medium: high glucose DMEM (GIBCO Invitrogen) with 10% fetal bovine serum 
(FBS; Atlanta Biologicals), 1% penicillin/streptomycin (GIBCO Invitrogen), and 1 ng/ml 
bFGF (PeproTech). Cells were used at passage three for monolayer experiments and passage 
two for 3D fibrin gel experiments. Observations were confirmed with four additional donors. 
 
Flow Cytometry 
 ASCs were assessed for surface expression of mesenchymal (CD73, CD105) and 
vascular markers (CD34, VEGFR2, CD31, αSMA). Detached cells were suspended in PBS 
containing 2% FBS and incubated with monoclonal antibodies conjugated to fluorescein 
isothiocyanate or phycoerythrin for 30 min at 4ºC. Cells were analyzed with a flow cytometer 
(BD Accuri C6). All antibodies were purchased from BD Biosciences. 
 
Monolayer Seeding Density 
 ASCs were seeded at 3000, 10000, or 20000 cells per cm2 and cultured for 14 days in 
endothelial induction medium (EIM). The composition of EIM was optimized in 




Medium-2 (EBM2; Lonza) supplemented with 2% FBS, 1% penicillin/streptomycin, 2 
ng/ml VEGF165 (PeproTech), 10 ng/ml bFGF, and 1 µg/ml L-ascorbic acid-2-phosphate 
(Sigma). Endothelial phenotype was assessed via quantitative RT-PCR and 
immunocytochemistry. The DNA content was assessed at various time points to evaluate 
growth patterns and final cell densities within the cultures. 
 
Vascular Morphogenesis in Monolayer 
 ASCs were seeded at 20000 cells per cm2 and cultured for up to 14 days in EIM. Cells 
were assayed extensively over several timepoints (0, 3, 7, 10, 14 days) and passages (2 
through 4) via immunocytochemistry for endothelial and perivascular markers. Day 0 
samples were taken 4 hours after seeding. Quantitative RT-PCR was also conducted on 
passage 3 cells after 1, 7, and 14 days. 
 
BrdU Incorporation 
 To identify proliferating cells in the culture, 10 µM bromodeoxyuridine (BrdU; Sigma) 
was added to culture medium for 24 hours. This was followed by washing and fixation with 
3.7% formaldehyde for 20 min. Samples were first immunostained for CD31 and αSMA in 
order to identify the subpopulations, followed by 10 min post-fixation to preserve the signal. 
DNA was denatured by incubating cells with 4N HCl plus 0.5% triton X-100 in PBS for 15 
min at room temperature. Following extensive washes, samples were incubated with mouse 
anti-BrdU conjugated to Alexa Fluor 647 (1:50; Invitrogen) overnight at 4ºC. Nuclei were 







The effects of platelet-derived growth factor-B (PDGF-B) signaling on the vascular 
morphogenesis in our system were assessed by blocking its receptor. ASCs were seeded at 
20000 cells per cm2 and cultured for 14 days in EIM supplemented either with vehicle only 
(dimethyl sulfoxide) or 50 µM tyrphostin AG1295 (Santa Cruz Biotechnology), a selective 
inhibitor of PDGF receptor (PDGFR) tyrosine kinase activity. Morphological effects were 
evaluated via immunocytochemistry. 
 
DNA Content 
 In order to evaluate proliferation, cells were grown in 24-well plates for 0, 3, 7, 10, or 14 
days and lysed with 250 µl of digestion buffer (10 mM Tris, 1 mM EDTA, 0.1% Triton X-
100, and 0.1 mg/mL proteinase K). Samples were incubated at 50 ºC overnight and DNA 
content was assessed using a PicoGreen dsDNA quantitation kit (Molecular Probes). Briefly, 
PicoGreen dye was added to samples in duplicate in black 96-well plates (50 µl sample, 50 µl 
1X Tris-EDTA buffer, 100 µl PicoGreen diluted 1:200) and read with a fluorescent plate 
reader (excitation 485 nm, emission 530 nm). DNA content was determined using a λDNA 




 Cells were grown in 12-well plates (n = 4 per group) for up to 14 days. Total RNA was 




spectrophotometer (Thermo Scientific). Reverse transcription was performed with 1 µg of 
total RNA using iScript cDNA Synthesis Kit (BioRAD). Complementary DNA was 
amplified using SYBR Green PCR Master Mix (Applied Biosystems) and a StepOnePlus 
Real-Time PCR System (Applied Biosystems). The primer sequences used for PCR analysis 
are listed in Table 2.1. Expression levels were calculated by the comparative CT method 
using GAPDH (seeding density study) as an endogenous reference gene. 
Table 2.1. Quantitative RT-PCR Primer Sequences 
Gene Primer Sequence (5’ – 3’) 
αSMA Forward CGGACCTTTGGCTTGGCTT Reverse TGGGGTGCGGACAGGAATT 





GAPDH Forward CACCCACTCCTCCACCTTTGA Reverse TCCACCACCCTGTTGCTGTAG 
VE-Cadherin Forward ATGGACCCTGATGCGGCTA Reverse TGTGACTCGGAAGAACTGGC 





vWF Forward GGGCTGTGTGGCAACTTTAAC Reverse ATAAGGGTCCGAGGTCAAGGT 
 
Immunocytochemistry 
Cells were fixed with 3.7% formaldehyde for 20 min, permeabilized with 0.2% triton X-
100 for 10 min, and then blocked with 10% normal donkey serum (Sigma) for 30 min. 
Briefly, samples were then incubated with antigen-specific primary antibodies overnight at 
4ºC, followed by secondary antibodies for 1 hour at room temperature. When using multiple 
primary antibodies from the same species (i.e. mouse), antigens were stained sequentially 




goat anti-mouse IgG monovalent Fab fragments (20 µg/ml) for 2 hours at room 
temperature, and then detected with Cy3-conjugated donkey anti-goat IgG. Antibody 
complexes were lightly fixed with 1.85% formaldehyde for 10 min, and cells were blocked 
with 10% normal goat serum (Sigma) for 30 min. Samples were then co-stained for the 
remaining antigens following standard protocol using species-specific secondary antibodies 
(DyLight 488- or 649-conjugated goat anti-mouse or anti-rabbit IgG, respectively). 
Coverslips were mounted in ProLong Gold Antifade Reagent (Invitrogen) containing DAPI, 
and imaged using a Zeiss Axio Observer inverted fluorescence microscope and a Zeiss LSM 
510 confocal microscope with 63x/1.4 oil objective. Primary antibodies were purchased 
from Santa Cruz Biotechnology [mouse anti-CD31 (1:50), mouse anti-vascular endothelial-
cadherin (VE-Cad; 1:50), rabbit anti-desmin (1:50), mouse anti-collagen IV (1:100)], Sigma 
[rabbit anti-von Willebrand factor (vWF; 1:200), rabbit anti-laminin (1:100)], and Invitrogen 
[mouse anti-alpha smooth muscle actin (αSMA; 1:50)]. All secondary antibodies were 
purchased from Jackson Immunoresearch and used at a 1:200 dilution. 
 
Image Analysis (Immunocytochemistry) 
 Morphological measurements of immunostaining were performed using Image J 
software (NIH). At least eight vessels per group were used for quantification of vessel length 
and width. Length was measured along the entire structure from tip to tip. For branched 
vessels, segment lengths were summed. The width of each vessel was averaged among 
discrete measurements (spaced ~25 µm apart) along the entire length of the vessel. The area 




three samples per group. Images were thresholded to measure percent positive area. All 
groups were normalized to “day 0” values. 
 
Spheroid Formation via Hanging Drop 
Cells were trypsinized and resuspended in culture medium containing 0.24% (w/v) 
methylcellulose (Sigma). Cell concentrations were varied (0.1, 0.4, or 1 x 106 cells/mL) to control the 
total cell number per spheroid. Cell suspensions were pipetted as 10 µl drops onto inverted Petri dish 
caps, which were then reverted and placed on dish bottoms containing sterile water to reduce 
evaporation. Dishes were incubated at 37 ºC overnight to allow cellular aggregation at the air-liquid 
interface. The dish caps were then flooded with PBS to allow bulk collection and transfer of the 
spheroids to conical tubes. 
 
Vascular Morphogenesis in 3D Fibrin Gels 
To study the effects of cellular aggregation on three-dimensional vascular assembly, cells were 
encapsulated either monodispersed (single-cell suspension) or aggregated into multicellular spheroids 
(1000, 4000, or 10000 cells each). Cells were resuspended at 4571 cells/µl in fibrinogen (8 mg/ml 
final; Sigma), followed by the addition of thrombin (2 U/ml final; Sigma) to initiate gelation. Fibrin 
gels (35 µl) were pipetted into 6-mm diameter wells and incubated at 37 ºC for 30 minutes to allow 
complete gelation prior to the addition of culture medium. Samples were cultured for two weeks in 
vascular medium: Endothelial Basal Medium-2 (Lonza), 6% FBS, 1% penicillin/streptomycin, 10 
ng/ml VEGF165, 1 ng/ml FGF-2, and 1 µg/ml L-ascorbic acid-2-phosphate (Sigma).  
 
Whole-Mount Immunostaining 
All incubation and washing steps were carried out at 4 ºC with gentle agitation. Samples 




min each. Fixed gels were carefully removed from their wells and transferred to 
microcentrifuge tubes for subsequent staining procedures. Gels were permeabilized and 
blocked for 4 hrs with 0.2% triton X-100 and 5% normal goat serum (Sigma) in PBS with 
0.1% Tween (PTw). Samples were then incubated overnight with primary antibodies diluted 
in blocking solution: mouse anti-CD31 (4 µg/ml; Santa Cruz Biotechnology) and rabbit anti-
laminin (7 µg/ml; Sigma). After three 1-hr washes in PTw, samples were incubated overnight 
with DyLight 488-conjugated goat anti-mouse and DyLight 649-conjugated goat anti-rabbit 
(both 1:400; Jackson ImmunoResearch) diluted in blocking solution, followed by three 1-hr 
washes in PTw. Lastly, samples were blocked in 5% normal mouse serum for 4 hrs, 
incubated overnight with Cy3-conjugated mouse anti-αSMA (7 µg/ml; Sigma), and then 
washed three times for 1 hr each. Gels were mounted in 70% glycerol in chamber slides and 
imaged using a Zeiss LSM 510 confocal microscope with a 5x objective. 
 
Image Analysis (Whole-Mount Immunostaining) 
 Confocal z-stacks of immunostained gels were z-projected and thresholded for 
subsequent quantification of vessel network parameters (n = 6 images per group). 
Thresholded images were analyzed with AngioQuant software[71] to quantify total vessel 
length, area, and interconnectivity. ImageJ software (NIH) was used to quantify pericyte 
coverage of vessels, which was defined as αSMA+ area within at least 5 µm of the abluminal 
face of vessel networks. Briefly, vessel networks were selected in the CD31 channel of 
thresholded image composites, and selections were enlarged by 5 µm at all edges. These 
enlarged selections were applied to the αSMA channel, and percent αSMA+ area within the 




of basement membrane protein deposited along the vessels, the enlarged vessel selection was 
applied to the non-thresholded laminin channel, and the mean pixel intensity within the 
selection area was quantified (denoted as “laminin mean intensity”). 
 
Statistical Analysis 
Quantitative data are expressed as mean ± standard error. Unpaired t-test was used for 
two-group comparisons. One-way ANOVA was used for multi-group comparisons, with 
Tukey’s post-hoc analysis. Significance levels denoted as *P < 0.05, **P < 0.01, ***P < 0.001. 
2.3 Results 
Cell Characterization 
The majority of ASCs were positive for mesenchymal markers, with a small minority 
(<1%) expressing vascular markers at passage 2 and 3 (Table 2.2). 
Table 2.2. Flow cytometric analysis of human ASCs. 
Surface Marker Passage 2 Passage 3 
Vascular Markers 
CD31 0.8% 0.1% 
CD34 5.2% 1.2% 
VEGFR2 0.3% 0.1% 
αSMA 1.1% 0.6% 
Mesenchymal Markers 
CD73 98.4% 99.4% 






Figure 2.1. Effects of cell seeding density on the endothelial phenotype of ASCs. (A) DNA 
content revealed that ASCs seeded at the two higher densities reached a final density of 65,000 
cells/cm2 within three days, while those seeded at 3,000 cells/cm2 took longer to reach a final density 
that was still significantly less. (B) mRNA expression of endothelial markers increased with 
increasing seeding density by day 14. (C) Morphologically, ASCs seeded at higher densities were 
more densely packed and aligned. (D) Only ASCs seeded at 20,000 cells/cm2 gave rise to CD31+ 
vessels. (E) Cells remained uniformly distributed when seeded at 3,000 and 10,000 cells/cm2, while 
those seeded at 20,000 cells/cm2 aggregated into dense clusters by day 14. Significance indicated as 
*P < 0.05. Scale bars = 100 µm (C-D) and 250 µm (E). 
 
Cell Seeding Density in Monolayer 
Passage 3 ASCs were cultured at 3000, 10000, and 20000 cells/cm2 for 14 days in EIM. 
ASCs seeded at the two higher densities attained a final density of approximately 65,000 
cells/cm2 as determined by DNA content by day 3 (20000 per cm2) or day 7 (10000 per cm2), 
at which they stayed for the remainder of the differentiation period. Cells seeded at 3000 
cells/cm2 grew to 50000 cells/cm2 by day 7 and remained constant thereafter, never attaining 
the density of the other two groups (Fig. 2.1A). At higher seeding densities there was 




(VEGFR-2) expression was not significantly affected by seeding density (Fig. 2.1B). After 
14 days, cells seeded at 10000 to 20000 cells/cm2 became densely packed with cells aligning 
locally with neighboring cells, while those seeded at 3000 cells/cm2 remained sub-confluent 
with random cell orientation (Fig. 2.1C). Positive staining for CD31 was only observed 
when cells were seeded at 20000 cells/cm2, with specific staining of vessel-like structures 
enveloped within dense cell clusters (Fig. 2.1D). Low magnification images of DAPI stains 
confirmed that the non-uniform aggregation occurred only in the 20000 cells/cm2 group, 
while those seeded at 3000 or 10000 cells/cm2 were uniformly distributed (Fig. 2.1E). In all 
subsequent experiments, cells were seeded at 20000 cells/cm2. 
 
Vascular Phenotypes and Morphology 
Vascular structures stained positively for three endothelial markers: CD31 located at cell 
junctions and filopodia, VE-cadherin located at cell junctions, and vWF with a granular 
pattern in the cytoplasm (Fig. 2.2A). Many of the cells surrounding the vessels were positive 
for pericyte markers (αSMA and desmin) (Fig. 2.2B). Vascular basement membrane 
proteins, collagen IV and laminin, were also present along vessel tracks (Fig. 2.2C). The 
pan-laminin antibody, which is reactive against all laminin isoforms, also faintly stained other 
cellular regions beyond the vessels. 
Optical slices from 63x confocal z-stacks revealed the relative locations of the cells 
comprising the vascular structures (Fig. 2.2D-F). Many of the αSMA+ cells were stretched 
out against the glass (Fig. 2.2D), blanketing the area beneath the endothelial vessels. Some 
of the αSMA+ cells were also visible along the sides or on top of vessels, assuming classic 




vessels (Fig. 2.2F), indicating that the vessels were fully encased within a three-dimensional 
cellular microenvironment. Many vessels contained large voids that appeared to be patent 
lumens (Fig. 2.2G) as shown in a cross-sectional view of one representative vessel, which 
measured an internal width of 9.7 µm and height of 5.4 µm, similar in size to a capillary (Fig. 
2.2H). Vessel tips were dense with filopodia (Fig. 2.2I). 
 
Figure 2.2. Vascular phenotypes and morphology. (A) Vessels stained positively for CD31, VE-
cadherin, and vWF (endothelial markers). (B) Cells clustered around the vessels were positive for 
αSMA and desmin (pericyte markers). (C) Vascular basement membrane proteins, collagen IV and 
laminin, were found along vessel tracks.  (D-F) Optical slices from a confocal z-stack: (D) αSMA+ 
cells (red) stretched out against the glass beneath the vessels. (E) CD31+ vessels (green) propagated 
on top of this layer of cells, with some αSMA+ cells invested alongside. (F) Additional αSMA-
/CD31- cells were located on top of the vessels (indicated by DAPI, blue), fully enveloping the 
vessel in a three-dimensional cellular environment. (G) Some vessels contained voids resembling 
patent lumens, demonstrated by the cross-section (dotted line) shown in (E). (F) Vessel tips were 





Time Course of Morphogenesis 
Four hours after seeding (“day 0”), the culture contained small numbers of αSMA+ cells 
(0.5%) and CD31+ cells (0.02%) (Fig. 2.4A), which similarly reflected the flow cytometry 
analysis. All CD31+ cells were in direct contact with another cell after attachment (Fig. 2.3). 
During the first week, individual CD31+ cells began to elongate into multicellular vessels, 
while the spatially independent αSMA+ cells increased in number and appeared to migrate 
towards the vessels (Fig. 2.4A). In the second week, αSMA+ cells co-localized with the 
vessels and continued to increase in number. DAPI stains revealed that cells began forming 
dense clusters around the vessels very early on, even before contact with αSMA+ cells (Fig. 
2.4B). From an orthogonal view, the initially flat vessel (Day 3) increased in height over time, 
while additional cells in the surrounding monolayer migrated on top of one another to form 
a multilayered cluster of cells (Fig. 2.4C). Quantification of vessel morphology revealed a 
steady temporal increase in vessel length (up to 1.2 mm at day 14) and pericyte coverage, 
while vessel width remained fairly constant (~12 µm) (Fig 2.4D). Expression of endothelial 
genes (CD31, VE-cadherin, VEGFR-2) and pericyte genes (αSMA) increased significantly 
over time (Fig 2.4E). 
 
Figure 2.3. Attachment of CD31+ cells. Four hours post-seeding, all CD31+ cells were directly 






Figure 2.4. Time course of vascular morphogenesis. (A) Four hours post-seeding (“day 0”), the 
culture contained small numbers of αSMA+ cells (0.5%; red) and CD31+ cells (0.02%; green; inset 
magnified). CD31+ cells elongated into vessels over time. αSMA+ cell density increased over time as 
they migrated towards the vessels. (B) DAPI staining (blue) of the same view fields illustrate dense 
cell clustering around the vessel. (C) Cross-sectional views of the vessels depict lumen formation, 
accompanied by cell migration on top of the vessel. Scale bars = 200 µm (A-B) and 5 µm (C). (D) 
Quantification of vessel morphology and pericyte area throughout the culture. (E) Gene expression 






Proliferation & Pericyte Recruitment 
BrdU incorporation revealed that the primary mode of vessel growth was proliferation 
(Fig. 2.5A), with most CD31+ cell nuclei staining positively for BrdU at days 3, 7, 10, and 
14 (single timepoint shown). αSMA+ cells distant from the vessel were most often BrdU+, 
whereas those in direct contact were not (Fig. 2.5B). 
Inhibition of PDGFR with significantly reduced αSMA+ cell vessel coverage (Fig. 2.5C) 
and their overall presence in the culture (Fig. 2.5D). Vessel length was not significantly 
affected by AG1295 (Fig. 2.5E); however, the vessels were significantly thinner (Fig. 2.5F). 
 
Figure 2.5. Proliferation and pericyte recruitment. ASCs were incubated with BrdU at multiple 
stages of vascular formation. (A) BrdU+ vessels (shown at day 7). Arrow indicates a dividing tip cell. 
(B) BrdU+ pericytes (shown at day 14). (C,D) Inhibition of PDGFR with AG1295 significantly 
reduced pericyte coverage. (E) Vessel length was not affected by AG1295, but (F) vessels were 
thinner. Scale bars = 50 µm (A) and 200 µm (B,C). Significance indicated as **P < 0.01 vs. vehicle. 
 
Serial Passaging 
 ASCs from passage 2 through 4 were grown to assess the effects of serial passaging on 




increasing passage number (Fig. 2.6A), which corroborates the flow cytometry data (Table 
2.2). This trend correlated with the degree of vascular growth by day 14, which was 
substantially greater at passage 2 and non-existent at passage 4 (Fig. 2.6B). Cells were used 
at passage 2 for all subsequent studies. 
 
Figure 2.6. Effects of serial passaging on the endothelial sub-population. (A) Vascular 
subpopulations four hours post-seeding. (B) Vessels after 14 days of culture. 
 
Cellular Aggregation in 3D Fibrin Gel 
To study the effects of cellular aggregation on vascular morphogenesis of ASCs in 3D 
fibrin gel, passage 2 cells were encapsulated either as a monodispersed cell suspension or 
spheroids containing various cell numbers (1000, 4000, or 10,000 cells per spheroid), with 
total cell number held constant (Fig. 2.7A). After 14 days of culture in VM, spheroid 
aggregates yielded significantly larger (up to 2.1-fold) and more interconnected (up to 5.5-
fold) vessel networks than monodispersed cells (Fig. 2.7B-D). Vessel coverage with 




spheroid (Fig. 2.7E-F). With the largest spheroid size (10000 cells per spheroid), the spatial 
distribution of the networks was less uniform. 
 
Figure 2.7. Effects of cellular aggregation on 3D vascular morphogenesis. (A) ASCs were 
encapsulated in fibrin gel as monodispersed cells or as spheroid aggregates (“sph”) of different sizes. 
(B) Vascular networks developed after 14 days of culture in vascular medium, staining positively for 
CD31 (green), αSMA (red), and laminin (blue). Compared to monodispersed cultures vascular 
networks derived from spheroids were longer (C), more interconnected (D), and displayed greater 
coverage by pericytes (E) and laminin (F). Scale bars = 500 µm. Significance indicated as *P < 0.05, 
**P < 0.01, or ***P < 0.001 versus monodispersed. 
2.4 Discussion 
 The vascular potential of ASCs makes them a viable and unique cell source for clinical 
therapeutics. This study demonstrates that ASCs are capable of spontaneously self-
assembling to form three-dimensional vascular networks that contain hollow lumens and are 




endothelial sub-population and coordinated heterotypic interactions amongst cells. The 
monolayer experiments illustrate these complex cellular behaviors and informed the cellular 
aggregation approach for the 3D fibrin gel experiment, which will be essential for 
subsequent tissue engineering studies. 
 In the monolayer experiments, vascular growth only occurred when ASCs were seeded at 
a high density (20000 cells per cm2), which allowed for direct contact of CD31+ cells with 
other cells immediately after plating. While cells seeded at 10000 cells per cm2 eventually 
proliferated to the same final cell density as those at 20000 cells per cm2 and presumably 
contained half the number of CD31+ cells at the start of the culture period, they did not 
exhibit CD31+ staining or vessel formation. This suggests that these early cellular 
interactions may be crucial to vascular assembly. 
 Intriguingly, the various subpopulations of ASCs appeared to recapitulate some aspects 
of classic vasculogenesis. During development, endothelial progenitors are induced by FGF-
2 and VEGF to elongate and proliferate into nascent vessels. The growing vessels secrete 
PDGF-B to recruit pericytes (PDGFR-β+) who migrate towards and wrap around the 
vessels for stability and support [72-74]. In our system, CD31+ cells elongated and 
proliferated to form vessel-like structures, while the proliferating αSMA+ cells were initially 
spatially independent. As the vascular structures continued to elongate, both αSMA+ and 
CD31-/αSMA- cells appeared to migrate towards the vessel, forming dense clusters of cells 
around the vessel stalks. These cells fully enveloped the vessel, such that the endothelial cells 
within experienced a three-dimensional microenvironment. This perivascular cell recruitment 
was blocked with the inclusion of a selective PDGFR inhibitor in the culture medium, 




Vessel tracks were lined with vascular basement membrane proteins, collagen IV and laminin, 
and the vessels themselves exhibited classic morphology, with a patent lumen, thin 
multicellular endothelial wall, and cells at sprouting tips containing numerous filopodia. 
 The serial passaging experiment revealed a significantly smaller percentage of CD31+ 
cells in the population, which were completely gone by passage 4. This correlated with a 
similar reduction in vascular density after culture. These findings indicate that this 
endothelial subpopulation, which likely originated from the adipose microvasculature, is lost 
with passaging and may be the most robust at earlier passages. Clinically, reducing the extent 
of cellular manipulation and ex vivo expansion is preferable for numerous reasons (preserving 
cellular potency, safety, cost, time, etc.); therefore in the case of ASCs, the loss of vascular 
potential is another motivating factor to use the cells at low passage or fresh SVF. 
An interesting observation from the monolayer experiments was that the cells 
spontaneously self-assembled into dense clusters of cells during vascular growth, suggesting 
that heterotypic cell-cell interactions were important to the process. Moving into a 3D fibrin 
gel system, we tested the hypothesis that facilitating cellular interactions through forced 
aggregation would promote more robust vascular assembly. We demonstrated that indeed, 
aggregating ASCs into spheroids prior to fibrin encapsulation significantly enhanced their 
vascular network density and interconnectivity, pericyte coverage, and deposition of vascular 
basement membrane. This novel finding complements previous work demonstrating that 
aggregation of pure endothelial cells into spheroids or on the surface of microbeads reduces 
apoptosis and greatly enhances vascular sprouting [75, 76]. ASCs specifically have been 




networks in vitro [47, 53]. Therefore, aggregation may also serve to bring the pericyte-like 
cells closer to the endothelial sub-population to help support and stabilize them. 
This spontaneous organization of endothelial and pericyte-like populations from ASCs 
has significant implications for their therapeutic applications. Multiple tissue engineering 
therapies have focused on generating capillary networks to vascularize grafts.  However, the 
key to facilitating long-term, stable vascular regeneration may lie in the ability to recruit 
perivascular cells to endothelial networks to provide support and vasoresponsive properties 
[77]. In skeletal muscle vascular remodeling, vessel expansion beyond capillary diameter is 
accompanied by investment by αSMA+ cells [78]. Interaction between endothelial cells and 
pericytes elicits the deposition of supportive vascular basement membrane [79, 80], and 
ultimately leads to stabilization, junctional integrity, and maturation [72, 80, 81]. Pericytes can 
also promote survival and resistance to vascular regression [82-84]. The unique properties of 
ASCs allow them to perform both roles concurrently. 
While donor-to-donor variability is a valid concern with ASCs, we have also 
demonstrated the ability of numerous additional donors to give rise to similar vascular 
structures in monolayer and fibrin gels.  Given that cellular heterogeneity was a key 
component of these findings, it will be important to understand how these findings differ 
depending on a wider variety of donor demographics and harvest techniques.  There may 
also be implications for methods used to culture and expand ASCs: is the trend towards 
homogeneity with continued passaging beneficial?  Ultimately, it may affect clinical 
application as the ability to harvest all of the necessary cells from a single procedure could 
potentially reduce cost and recovery time for the patient. Nevertheless, additional studies are 





In summary, we have demonstrated that minority sub-populations of vascular cells 
persist in early passage ASCs and are capable of extensive proliferation and spontaneous 
self-assembly to form pericyte-stabilized vascular networks. Close cellular contact and 
endogenous biological signaling are crucial to encouraging this self-assembly process. 
Further studies are required to determine whether vascular morphogenesis can occur in the 
culture without negatively impacting the differentiation potential of the remaining non-
vascular cells in the culture. However, these studies set an important foundation upon which 






Chapter 3  
Vascularized Bone Model, Part I: 
Platelet-Derived Growth Factor 
3.1 Introduction and Background 
 Tissue engineering approaches to generate vascularized bone grafts could potentially 
revolutionize treatment of massive bone loss due to traumatic injuries, cancer, and 
congenital defects. Vasculature is essential to the long-term functional outcomes of a large 
bone graft to ensure sufficient nutrient delivery and post-implantation viability. While 
vasculature plays a necessary and intimate role in bone development, inducing the formation 
of vascularized bone tissues in vitro remains a challenge because the factors that promote 
each lineage may be detrimental to the other [18, 19, 85]. This incompatibility has led 
researchers to develop various methods to encourage vasculature to form concurrently or in 
a sequential manner with osteogenic differentiation, including: precise dosing regimens of 
induction factors [17, 21, 26], various cocktail media [86, 87], and pre-treating multiple cell 
types separately followed by recombination in a unified graft [17, 24-26, 88]. Yet each of 
these approaches relies on mitigating competing factors, resulting in an imbalance with sub-
optimal results for one or both of the tissue components. Therefore, there is still an unmet 
need for a clinically translatable approach to induce robust formation of both vasculature 




Adipose-derived stromal/stem cells (ASCs) are a promising, clinically relevant cell source 
to supply both the osteogenic and vascular components of a vascularized bone graft. Our 
prior studies showed that vascular assembly of ASCs is dependent on heterotypic cell-cell 
interactions, specifically through dense clustering of cells and endogenous platelet-derived 
growth factor (PDGF) signaling. This endogenous behavior is reminiscent of what occurs in 
native tissues, as proliferating endothelial cells in nascent vessels secrete PDGF-BB to recruit 
pericytes for vascular maturation and stabilization [72, 81]. PDGF-BB is also a major factor 
secreted by activated platelets to initiate repair mechanisms in wounded tissues such as bone 
[89-91] (Fig. 1.1A). A number of studies have demonstrated that in vivo administration of 
exogenous PDGF-BB significantly enhances bone formation [92-94]. Yet, in vitro studies 
with MSCs have reported that while exogenous PDGF-BB induces greater proliferation, it 
has no effect on [95-97], or may even be inhibitory to [98, 99], osteogenic differentiation. 
With regards to ASCs, it has been shown that during osteogenic differentiation their 
expression of PDGF receptor β (PDGFR-β) is upregulated [100]. However, the ability of 
PDGF-BB signaling to directly enhance the osteogenic capabilities of ASCs is not known. 
 The goal of this study is to develop an induction protocol to maximize the co-
development of vasculature and bone by ASCs. We do so by first optimizing the 
concentrations and timing of angiogenic and osteogenic factors. We then assess the 
hypothesis that exogenous PDGF-BB can synergize complex tissue formation by enhancing 





3.2 Materials and Methods 
ASC Isolation 
 Cellular isolation was performed at the Stem Cell Biology Laboratory, Pennington 
Biomedical Research Center, under an Institutional Review Board approved protocol 
(#PBRC 23040) according to published methods [67]. Briefly, fresh human subcutaneous 
adipose lipoaspirate was obtained under informed consent from female donors (n = 2) 
undergoing elective liposuction surgery, with an average age of 46 years and average body 
mass index of 29.1. The lipoaspirate tissue was processed to isolate the adherent population 
from the SVF, as previously described [101]. The adherent population (“passage 0”) was 
trypsinized and cryopreserved [68] for shipment to Johns Hopkins University. 
 
ASC Expansion & Characterization 
ASCs were expanded in growth medium: high glucose DMEM (GIBCO Invitrogen) 
with 10% FBS (Atlanta Biologicals), 1% penicillin/streptomycin (GIBCO Invitrogen), and 1 
ng/ml FGF-2 (PeproTech). Cells were used at passage two for all experiments. Cell 
phenotype was examined via flow cytometry for mesenchymal (CD73, CD105) and vascular 
markers (CD31, CD34, VEGFR-2, alpha-smooth muscle actin (αSMA)). Briefly, detached 
cells were incubated with monoclonal antibodies conjugated to FITC or PE (BD 
Biosciences) for 30 min at 4 ºC. Cells were analyzed with a flow cytometer (BD Accuri C6). 
 
Spheroid Formation via Hanging Drop 
Cells were trypsinized and resuspended at a concentration of 400,000 cells/ml in culture 




as 10 µl drops onto inverted Petri dish caps, which were then reverted and placed on dish 
bottoms containing sterile water to reduce evaporation. Dishes were incubated at 37 ºC 
overnight to allow cellular aggregation at the air-liquid interface. The dish caps were then 
flooded with PBS to allow bulk collection and transfer of the spheroids to conical tubes. 
 
Fibrin Encapsulation 
Settled spheroid pellets were resuspended in fibrinogen (8 mg/ml final; Sigma), followed 
by the addition of thrombin (2 U/ml final; Sigma) to initiate gelation. Fibrin gels (35 µl) 
containing 40 spheroids each were pipetted into 6-mm diameter wells and incubated at 37 ºC 
for 30 minutes to allow complete gelation prior to the addition of culture medium. Samples 
were then cultured for two to three weeks, depending on the experiment, with media 
changed every other day. 
 
Media Preparation 
 Vascular medium (VM) consisted of: Endothelial Basal Medium-2 (Lonza), 6% FBS, 1% 
penicillin/streptomycin, 10 ng/ml VEGF165, 1 ng/ml FGF-2, and 1 µg/ml L-ascorbic acid-
2-phosphate (Sigma). For monolayer osteogenesis experiments, control medium consisted of 
low glucose DMEM (GIBCO Invitrogen), 6% FBS, and 1% penicillin/streptomycin; 
Osteogenic Medium (OM) consisted of control medium plus 10 mM β-glycerophosphate 
(Sigma) and 50 µM L-ascorbic acid-2-phosphate. For osteogenesis in fibrin gels, OM also 
included 10 ng/ml VEGF165 and 1 ng/ml FGF-2 to support vascular viability. The 
composition of FGF-2 and dexamethasone in VM and OM were optimized to support both 




growth factors (i.e. PDGF-BB or bone morphogenetic protein-2 (BMP-2)) depending on the 
experiment. All growth factors were purchased from PeproTech. 
 
Osteogenic Differentiation Assays 
 For monolayer experiments, ASCs were seeded at 5000 cells/cm2 and cultured in either 
control medium or OM for 21 days, with the addition of either PDGF-BB or PDGF 
receptor inhibitor tyrphostin AG1295 (Santa Cruz Biotechnology). Mineralization was 
assessed via Alizarin Red S staining and quantification of calcium content. For fibrin gel 
experiments, samples were cultured in VM for up to 8 days followed by up to 12 days of 
OM supplemented with VEGF and FGF-2. Mineralization was assessed via quantification of 
calcium content normalized to DNA content. 
 For Alizarin Red S staining, monolayers were washed twice with PBS, fixed with 3.7% 
formaldehyde for 20 min, and then washed again three times. Samples were subsequently 
incubated for 10 min with 40 mM Alizarin Red S (Sigma) and washed extensively prior to 
imaging. To quantify calcium content in each sample, monolayers or whole fibrin gels were 
washed twice with PBS and then incubated with 0.5 N HCl overnight at 4 ºC with agitation. 
Calcium content in the sample supernatants was quantified using a colorimetric Calcium 
LiquiColor Test (Stanbio). DNA content was quantified using a PicoGreen dsDNA 
quantitation kit (Molecular Probes) as previously described [101]. 
 
Whole-Mount Immunostaining 
All incubation and washing steps were carried out at 4 ºC with gentle agitation. Samples 
were fixed with 3.7% formaldehyde for 3 hrs, and then washed with PBS three times for 30 




microcentrifuge tubes for subsequent staining procedures. Gels were permeabilized and 
blocked for 4 hrs with 0.2% triton X-100 and 5% normal goat serum (Sigma) in PBS with 
0.1% Tween (PTw). Samples were then incubated overnight with primary antibodies diluted 
in blocking solution, followed by three 1-hr washes in PTw. Primary antibodies included: 
mouse anti-CD31 (4 µg/ml; Santa Cruz Biotechnology) and either rabbit anti-laminin (7 
µg/ml; Sigma) or rabbit anti-osteocalcin (10 µg/ml; Santa Cruz Biotechnology). Samples 
were incubated overnight with DyLight 488-conjugated goat anti-mouse and DyLight 649-
conjugated goat anti-rabbit (both 1:400; Jackson ImmunoResearch) diluted in blocking 
solution, followed by three 1-hr washes in PTw. Lastly, samples were blocked in 5% normal 
mouse serum for 4 hrs, incubated overnight with Cy3-conjugated mouse anti-αSMA (7 
µg/ml; Sigma), and then washed three times for 1 hr each. Gels were mounted in 70% 
glycerol and imaged using a Zeiss LSM 510 confocal microscope with a 5x objective. 
 
Image Analysis 
 Confocal z-stacks of immunostained gels were z-projected and thresholded for 
subsequent quantification of vessel network parameters (n = 6 images per group). 
Thresholded images were analyzed with AngioQuant software [71] to quantify total vessel 
length, area, and interconnectivity. ImageJ software (NIH) was used to quantify pericyte 
coverage of vessels, which was defined as αSMA+ area within at least 5 µm of the abluminal 
face of vessel networks. Briefly, vessel networks were selected in the CD31 channel of 
thresholded image composites, and selections were enlarged by 5 µm at all edges. These 
enlarged selections were applied to the αSMA channel, and percent αSMA+ area within the 




the αSMA+ population was quantified by measuring the mean pixel intensity within the non-
thresholded αSMA channel viewfield. Lastly, to quantify the amount of basement membrane 
protein deposited along the vessels, the enlarged vessel selection was applied to the non-
thresholded laminin channel, and the mean pixel intensity within the selection area was 
quantified (denoted as “laminin mean intensity”). 
 
Statistical Analysis 
 Quantitative data are expressed as mean ± standard error. Multi-group comparisons 
were determined by one-way ANOVA with Tukey’s test for post-hoc analysis. Significance 
levels are denoted as *P < 0.05, **P < 0.01, and ***P < 0.001. 
3.3 Results 
Cell Characterization 
 ASCs at passage 2 were primarily positive for mesenchymal markers CD73 (98.4%) and 
CD105 (80.1%) and predominantly negative for markers of the endothelial lineage (5.2% 
CD34+; 0.3% VEGFR+; 0.8% CD31+) or the pericyte marker αSMA (1.1%). 100% of 
CD31+ cells were also positive for PDGFR-β, indicating that these cells are capable of 
responding to PDGF-BB directly. 
 
Media Component Optimization 
 The concentrations of dexamethasone and FGF-2 were optimized separately in OM and 
VM formulations to support both tissue components. Osteogenic cultures yielded 




nM dexamethasone (Fig. 3.1A,B). In vascular cultures, dexamethasone substantially 
inhibited vessel network growth, while increasing pericyte coverage in a dose-dependent 
manner (Fig. 3.1C-E). Addition of FGF-2 increased vessel width (Fig. 3.1C), and induced a 
slight increase in vessel network length and pericyte coverage. 
 
Figure 3.1. Effects of dexamethasone and FGF-2 on each lineage. (A) Alizarin Red S staining of 
mineral in osteogenic monolayers. (B) Quantification of calcium content in osteogenic monolayers. 
(C) Vascular networks in 3D fibrin gel. Quantification of vessel network length (D) and pericyte 
coverage of vessels (E). Scale bar = 500 µm. Significance indicated by brackets in (B,D,E) as *P < 
0.05, **P < 0.01, or ***P < 0.001. Significance indicated in (B) as ##P < 0.01 or ###P < 0.001 
versus D100-F0, and all OM groups were significantly greater (P < 0.001) than control. 
Abbreviations: X nM dexamethasone (“DX”); Y ng/ml FGF-2 (“FY”). 
 
Sequential Addition of Factors 
 To determine the effects of osteogenic factors on vascular morphogenesis, fibrin-




to OM for the remaining culture period (Fig. 3.2A). All groups were cultured for a total of 
12 days. ASCs cultured in VM for 8 days prior to the addition of osteogenic factors yielded 
3.2-fold longer vascular networks than those cultured in OM for the entire period (Fig. 
3.2B). Interestingly, the mean αSMA+ intensity increased significantly with increasing length 
of time in OM (Fig. 3.2C), with an apparent increase in the number of αSMA+ and a 
reduction in their association with the nearby vessels. Extended culture in OM yielded 2.4-
fold less laminin deposition around vessels than in VM (Fig. 3.2D). Thus, while vascular 
factors were still present in OM, delaying the addition of osteogenic factors by at least 8 days 
provided more favorable conditions to induce vascular network growth. This sequential 





Figure 3.2. Sequential addition of factors. (A) Fibrin-encapsulated spheroids were cultured for 0, 
4, 8, or 12 days in vascular medium (VM) before switching to osteogenic medium (OM). All samples 
were cultured for 12 days. (Scale bar = 500 µm). Total vascular network length (B) and laminin 
coverage (D) were significantly higher when OM was delayed by several days whereas αSMA staining 
intensity increased substantially with longer culture periods in OM (C). (B-D) Significance indicated 
as *P < 0.05, **P < 0.01, or ***P < 0.001 versus 0 days. (E) The step-wise protocol resulted in early 
mineral deposits being deposited in the vicinity of established vessels (arrows). Scale bar = 50 µm. 
 
Independent Effects of Exogenous PDGF-BB on Each Lineage 
 The effects of exogenous PDGF-BB on osteogenic differentiation and vascular 
morphogenesis of ASCs were studied independently. ASCs were cultured in OM for 21 days 
with the addition of either PDGF-BB (0, 2, or 20 ng/ml) or PDGF receptor inhibitor 
AG1295 (0, 1, or 10 µM). In the presence of exogenous PDGF-BB, ASC calcium deposition 
was significantly increased in a dose-dependent manner throughout the culture (Fig. 3.3A) 
as well as on a per cell basis (Fig. 3.3B). In the presence of AG1295, total calcium 
deposition was decreased in a dose-dependent manner (Fig. 3.3A), whereas calcium 
deposition per cell was unchanged relative to the OM only group with AG1295 (Fig. 3.3B). 
 In a separate experiment, fibrin-encapsulated spheroids were cultured in VM for 14 days 
with the addition of PDGF-BB or AG1295. Addition of low concentration (2 ng/ml) 
PDGF-BB resulted in a slight, 1.4-fold increase in total vessel length (Fig. 3.3C-D). Overall 
however, PDGF stimulation did not have statistically significant effects on total vessel length 
(Fig. 3.3D). Vessels were noticeably wider with the addition of 20 ng/ml PDGF-BB (Fig. 
3.3C). This was reflected quantitatively with statistically larger total vessel area divided by 
total vessel length (P < 0.001, data not shown). Pericyte coverage was reduced substantially 
by 2.9 fold in the presence of exogenous PDGF-BB, and only slightly reduced with the 





Figure 3.3. Independent effects of exogenous PDGF-BB on each lineage. Mineralization in 
osteogenic monolayers indicated by (A) Alizarin Red S and (B) calcium quantification. A separate 
experiment in 3D fibrin gel demonstrates vessel growth and pericyte coverage (C-E). Scale bar = 500 
µm. Significance indicated by brackets in (B,D,E) as *P < 0.05. Significance indicated in (B) as 
###P < 0.001 vs. PDGF groups. All OM groups were significantly greater (P < 0.001) than control. 
 
Combined Effects of Exogenous PDGF-BB on Vascularized Bone 
 The effects of PDGF-BB on the co-development of vasculature and bone within the 
same culture were assessed by inducing fibrin-encapsulated spheroids in a sequential manner 
(VM for 8 days followed by OM for 12 days) with either 0, 2, or 20 ng/ml PDGF-BB added 
throughout. Exogenous PDGF-BB resulted in significantly greater vascular density and 
osteogenic differentiation than cultures without PDGF-BB (Fig. 3.4D). Specifically, vascular 




and calcium content per cell was 5.2-fold greater (Fig. 3.4H). Osteocalcin production was 
semi-quantitatively measured to be 1.4 fold greater as well (Fig. 3.4C,G). Conversely, αSMA 
intensity was 2.1-fold less in the presence of 20 ng/ml PDGF-BB (Fig. 3.4B,F).  
 
 
Figure 3.4. Combined effects of exogenous PDGF-BB on vascularized bone. Fibrin-
encapsulated spheroids were cultured for 8 days in VM, followed by 12 days of OM with 0, 2, or 20 
ng/ml of PDGF-BB added throughout. Total vessel length (A,E), osteocalcin production (C,G), and 
calcium deposition (H) increased while αSMA staining intensity (B,F) decreased with increasing 






Figure 3.5. Direct comparison of PDGF-BB and BMP-2 on vascularized bone. FVibrin-
encapsulated spheroids were induced to form vascularized bone (8 days VM plus 12 days OM) with 
20 ng/ml of either PDGF-BB or BMP-2. BMP-2 induced no significant changes in either vascular 
network length (A,E) or calcium content (H) versus control, whereas PDGF-BB was substantially 
greater than both. (B,F) αSMA staining intensity was much greater with BMP-2 versus PDGF-BB, 
but only slightly greater than control. (C,G) Osteocalcin staining intensity was similar between 






In a similar experiment, we directly compared PDGF-BB with BMP-2 to determine 
whether these results are unique to PDGF-BB, as BMP-2 has also been shown to be both 
pro-osteogenic and pro-angiogenic. Encapsulated spheroids were cultured in VM for 8 days 
followed by OM for 12 days with the addition of either 20 ng/ml PDGF-BB or 20 ng/ml 
BMP-2. Cultures with PDGF-BB resulted in 4.2 fold greater calcium deposition and 5.6 fold 
greater calcium per cell than those with BMP-2 (Fig. 3.5H). Total vascular network length 
was also 2.3 fold higher in the presence of PDGF-BB than BMP-2 (Fig. 3.5A,E). 
3.4 Discussion 
 Pre-vascularizing tissue-engineered grafts prior to implantation has been shown to 
accelerate anastomosis with host vasculature and increase the survival of the tissue construct 
[13, 102, 103]. However, engineering vascularized bone has been a challenge in that the 
factors that are traditionally used in differentiation medium to induce either osteogenic 
differentiation or angiogenic behaviors can be mutually inhibitory when combined in mixed 
cultures [17]. The mutual inhibition is particularly devastating for the vascular component, as 
vessels have proven to be delicate and unstable in the presence of osteogenic cues in vitro. 
This study has demonstrated that exogenous PDGF-BB helps circumvent these issues by 
enhancing vascular growth and stability, as well as promoting robust osteogenic 
differentiation and mineralization. This is the first demonstration of cooperative growth 
yielding robust vascular networks within dense mineralized matrix. 
 In the current study, vascular growth by ASCs was severely limited in the presence of 
osteogenic factors, β-glycerophosphate and higher concentration ascorbic acid, despite the 




initiator of mineralization, as cells cannot synthesize their own phosphate. However, it may 
be a possible source of vascular inhibition after it is broken down into inorganic phosphate 
by alkaline phosphatase activity [104]. High inorganic phosphate levels (> 2.5 mM) have 
been shown to induce endothelial cell apoptosis via increased generation of reactive oxygen 
species [20]. To compensate for this, delaying the addition of osteogenic factors by one week 
allowed the vessels to grow and establish stable networks prior to inducing osteogenic 
differentiation of the non-endothelial sub-population. This sequential process is similar to 
what occurs in bone development and fracture repair in which invading vasculature is a 
prerequisite for the entry of osteogenic progenitors and subsequent mineralization [105, 106] 
(Fig. 1.1B,C). This established vascular network serves to bring nutrients and progenitor 
cells to the highly active site of regeneration [89, 107], as well as serving as a template around 
which mineral will be deposited [106]. Establishment of vascular networks prior to 
osteogenesis helped to stabilize the networks with pericytes and increased laminin deposition, 
possibly shielding them from the inhibitory factors in the second phase. 
This study has demonstrated that exogenous PDGF-BB at 20 ng/ml further helps to 
circumvent issues of mutual inhibition by enhancing both the osteogenic and vascular 
development of ASCs. In osteogenic cultures, PDGF-BB markedly increased mineral 
deposition overall and on a per cell basis. Conversely, addition of the inhibitor AG1295 
reduced overall mineral deposition, while the relative amount per cell remained unchanged. 
These results suggest that PDGF signaling might not be required for osteogenic 
differentiation of ASCs, but it may significantly amplify their responsiveness to osteogenic 
cues, leading to the production of greater amounts of mineral. This response may be 




no effect or even an inhibitory effect on the osteogenic differentiation bone marrow-derived 
MSCs [95-99]. 
In vascular cultures, PDGF signaling had minimal effects on vascular network properties, 
with only low levels of exogenous PDGF-BB contributing to a slight increase in network 
density. PDGF signaling did, however, significantly affect pericyte coverage of the vessels. 
Exogenous PDGF-BB caused a significant decrease in pericyte coverage, likely by masking 
endogenous gradients and stimulating the pericytes to migrate randomly. Interestingly, the 
inhibitor AG1295 did not significantly reduce pericyte coverage. This is possibly a result of 
the cellular aggregation prior to encapsulation, in which the growing vessels are already in 
direct contact with pericyte-like cells, thereby reducing the necessity to recruit pericytes via a 
PDGF gradient. 
PDGF-BB appeared to play a different role in maintaining vascular stability in the 
presence of osteogenic factors. Using a sequential protocol of a vascular phase followed by 
an osteogenic phase, the addition of 20 ng/ml PDGF-BB was able to support vascular 
growth and stability as well as amplify mineral deposition. There are some hypotheses in the 
literature about how exactly this occurs. A recent review discusses the possible roles of 
PDGF-BB signaling in terms of bone fracture repair [89]. When bone is injured, high 
concentrations of PDGF-BB may cause vascular pericytes and other osteoprogenitors to 
populate the injury site and increase production of mineral. These cells may also respond to 
PDGF-BB by secreting higher levels of VEGF to recruit angiogenesis towards the 
regenerating tissue [89, 108]. In the case of our own study, this increased endogenous 
production of VEGF may be furthering the stability of established vessels in the osteogenic 




to PDGF-BB via PDGF receptors. In this study, 100% of CD31+ cells were PDGFR-β+, 
suggesting that they are indeed capable of sensing PDGF-BB. However, further studies are 
needed to identify the specific mechanisms underlying these morphogenic events within the 
ASC cultures. 
An interesting observation in our study was that the expression of αSMA changed 
dramatically throughout the induction period. αSMA aids cellular contractility and is 
primarily expressed by vascular smooth muscle cells and pericytes [109]. In our study, initial 
ASC cultures exhibited only 1% αSMA positive population. Prior to the application of 
osteogenic supplements, αSMA+ cells were primarily located in perivascular locations. 
However, following exposure to osteogenic supplements, there was a dramatic increase in 
the intensity and number of cells expressing this marker. This change in expression profile 
reflects what is observed in native mineralizing bone: Osteoblasts upregulate expression of 
αSMA during active mineralization, whereas resting osteoblasts and osteocytes do not 
express αSMA [110]. However, the current study also showed that ASCs treated with 20 
ng/ml PDGF-BB in the presence of osteogenic cues exhibited substantially lower αSMA 
expression at day 20 than those cultured without PDGF-BB even though the mineral 
content in PDGF-BB cultures was significantly higher suggesting that a αSMA expression 
alone does not directly correlate with increased osteogenesis.  
 Lastly, we examined whether this mutually beneficial response exhibited by cells in the 
presence of PDGF-BB was unique by comparison to BMP-2, the most widely studied and 
clinically applied pro-osteogenic growth factor. BMP-2 has been shown to significantly 
enhance osteogenic differentiation and in vivo bone growth [111], as well as indirectly 




shows through direct comparison that PDGF-BB is considerably more effective than BMP-2 
at both amplifying osteogenic differentiation of ASCs and maintaining vascular stability 
when applied at 20 ng/ml. Importantly, this concentration of PDGF (20 ng/ml) is only 5 to 
10 times the concentration in normal human serum [113] and is within the physiological 
range measured during bone injury [114]. Clinical safety is imperative, as supra-physiological 
concentrations may lead to adverse side effects such as bone overgrowth and inflammation 
[115]. Together, these results indicate that, in combination with ASCs, PDGF-BB may be 
better suited than BMP-2 for the enhancement of both bone and vasculature at physiological 
concentrations. 
3.5 Conclusions 
 In summary, we have demonstrated that ASCs can be driven to form robust vascularized 
bone with the addition of exogenous PDGF-BB. Combined with the delayed addition of 
osteogenic cues, this protocol recapitulates intrinsic regenerative profiles that instruct the 
cells to grow into complex tissue grafts with less manipulation compared to existing models. 
This induction protocol using physiological levels of PDGF-BB can be utilized to engineer 






Chapter 4  
Vascularized Bone Model, Part II: 
Inflammatory Cytokines 
4.1 Introduction and Background 
 Cell-based approaches to bone tissue engineering provide a tremendous opportunity to 
repair large, non-healing bone defects by enriching the site with regenerative cells. However, 
the potential benefit is hampered by the need for rapid vascularization to maintain cell 
viability and also provide complex signaling cues between vasculature, infiltrating 
inflammatory cells, and osteoprogenitors that guide tissue repair and maturation. Therefore, 
coupling vascularization strategies with bone tissue engineering may greatly improve 
functional outcomes. 
 Our previous studies established a step-wise protocol to engineer robust vascularized 
bone in vitro with the addition of exogenous platelet-derived growth factor (PDGF), which 
significantly increased both vascularization and mineralization. PDGF is a key regenerative 
cue that is released by activated platelets following bone injury [89], raising the question of 
how other elements of normal bone repair may affect bone tissue engineering. 
 Immediately following bone injury, there is an acute inflammatory phase in which 
activated platelets and macrophages release a host of factors, including PDGF and pro-




initiation of healing through the recruitment and activation of regenerative cells, as well as 
promoting re-vascularization. While normally thought of as intrinsically damaging to tissue 
repair, pro-inflammatory cytokines such as tumor necrosis factor-α (TNF) have been shown 
to promote tissue-healing processes in some cases. For example, exogenously applied TNF 
has been shown to promote angiogenesis in vivo [119, 120] and in vitro by inducing the 
endothelial tip cell phenotype [121]. This response appears to be highly sensitive to the 
timing and dosage, as there are also many reports of the anti-angiogenic effects of TNF 
[121-124]. In the case of bone, TNF has been shown to improve bone fracture healing in vivo 
[125, 126] and osteogenic differentiation of stem cells in vitro [127-130]. 
 The current study aims to understand whether TNF may benefit the development and 
maintenance of vascular networks within engineered osteogenic tissue. In particular, we 
study the effects of TNF dose and timing, as well as its combined effects with PDGF. In 
addition, we generate osteogenic grafts within composite scaffolds to study tissue maturation 
and integration in vivo. We demonstrate that recapitulating the biochemical environment 
within normal bone healing cascades through the inclusion of the inflammatory mediator 
TNF improves vascularization of tissue engineered osteogenic grafts. 
4.2 Materials and Methods 
Ethics Statement 
 Human subcutaneous adipose tissue was obtained in the form of lipoaspirate from 
female donors (n = 3) with written informed consent under the approval of the Johns 
Hopkins Medicine Institutional Review Board. All animal procedures were conducted in 




National Institutes of Health, with every effort taken to minimize animal suffering. The 
study protocol was approved by the Johns Hopkins University Animal Care and Use 
Committee. Johns Hopkins University is accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care International and holds Public Health Service 
Animal Welfare Assurance Number A-3272. 
 
ASC Isolation and Culture 
 ASCs were isolated from lipoaspirate tissue as previously described [101]. Briefly, tissue 
was digested with collagenase (1 mg/mL; Worthington Biochemical Corp.) to isolate the 
stromal vascular fraction of cells. These cells were plated onto tissue culture plastic, and were 
termed “passage 0 ASC” when they reached 80-90% confluence. ASCs were used at passage 
2 for all experiments. Growth medium consisted of: high-glucose DMEM (Gibco 
Invitrogen) with 10% fetal bovine serum (FBS; Atlanta Biologicals), 1% 
penicillin/streptomycin (Gibco Invitrogen), and 1 ng/mL basic fibroblast growth factor 
(FGF-2; PeproTech). Experimental results were verified by repeating studies with cells from 
three separate donors. 
 
Flow Cytometry 
 Passage 2 ASCs were assessed via flow cytometry for surface expression of mesenchymal 
(CD73, CD105, PDGFR-β) and endothelial markers (CD31, CD34). Briefly, cells were 
suspended in phosphate buffered saline (PBS) containing 2% FBS and incubated with 




cytometer. Antibodies were purchased from Santa Cruz Biotech (PDGFR-β) and BD 
Biosciences (all others). 
 
Cell Aggregation Via Suspension Culture 
 Cells were trypsinized and resuspended at a concentration of 200,000 cells/mL in growth 
medium containing 0.24% (w/v) methylcellulose (Sigma). The cell suspension was pipetted 
into 10-cm petri dishes coated with 2% (w/v) agarose to minimize cellular adherence to the 
dish. After overnight suspension culture, cellular aggregates (Fig. 4.1) were collected with a 
pipet, and then centrifuged before encapsulation procedures. 
 
Figure 4.1. Morphology of suspension aggregates.  
 
Cell Encapsulation in Fibrin Gels 
 Cells were suspended in fibrinogen (8 mg/mL final; Sigma) and thrombin (2 U/mL final; 
Sigma) at a final cell concentration of 5000 cells/µL. Fibrin gels were formed by pipetting 35 
µL of gel solution into 6-mm diameter wells and incubating at 37 ºC for 30 min to allow 
complete gelation before the addition of culture medium. Samples were cultured for 2 to 3 





PCL Scaffold Fabrication and Seeding 
 Polycaprolactone (PCL) was utilized as the base scaffold material for these studies to 
allow handling and implantation of grafts, as well as its biocompatibility, mechanical 
properties, and in vivo stability [131, 132]. PCL scaffolds were produced as previously 
described [133]. Briefly, a Syil X4 CNC mill (Syil America) was converted into a custom-built 
3D printer with a hot melt pressure extruder attached to the spindle. PCL pellets 
(Polysciences Inc., Warrington, PA) were melted to 80ºC and extruded at a linear speed of 
2.7 mm/sec through a 460-µm nozzle. Scaffold sheets were printed with a 0/90º lay-down 
pattern and 40% infill density. Cylindrical scaffolds were punched from these sheets with 
dimensions of 4 mm diameter x 2 mm height (Fig. 4.2). Scaffolds were treated with 3M 
sodium hydroxide for 1 hour to increase hydrophilicity, followed by 1 hour of 70% ethanol 
to sterilize. Before cell seeding, rinsed scaffolds were incubated with growth medium at 37 
ºC for 1 hour, then blotted on sterile Kimwipes immediately prior to seeding. Cells were 
seeded into the scaffold pore spaces with fibrin gel to facilitate vascular assembly and rapid 
encapsulation of cells. Briefly, 20 µL of fibrin gel solution containing 6 x 105 cells was 
pipetted into scaffold pore spaces and allowed to solidify at 37 ºC for 30 minutes. 
 
Figure 4.2. Cylindrical polycaprolactone scaffold. Dimensions: 4 mm diameter x 2 mm height, 






 Vascular Medium (VM) consisted of endothelial basal medium-2 (Lonza), 6% FBS, 1% 
penicillin/streptomycin, 10 ng/mL vascular endothelial growth factor-165 (VEGF; 
PeproTech), 1 ng/ml FGF-2, and 1 µg/mL L-ascorbic acid-2-phosphate (Sigma). For 
monolayer osteogenic differentiation experiments, Control Medium consisted of low glucose 
DMEM (GIBCO Invitrogen), 6% FBS, and 1% penicillin/streptomycin; Osteogenic 
Medium (OM) consisted of Control Medium plus 10 mM β-glycerophosphate (Sigma) and 
50 µM L-ascorbic acid-2-phosphate. To support both vascular growth and osteogenic 
differentiation, OM was further supplemented with 10 ng/ml VEGF and 1 ng/ml FGF-2 
for studies within fibrin gels and PCL scaffolds. 
 
Osteogenic and Vascular Induction 
 For monolayer experiments, ASCs were seeded at 5000 cells/cm2 and cultured in either 
Control Medium or OM for 21 days. Mineralization was assessed via Alizarin Red S staining, 
as well as quantification of calcium and DNA content, as previously described [23]. For 
fibrin gel and scaffold experiments, vascular morphogenesis was induced by culturing cells in 
VM for up to 14 days. Dual (vascular and osteogenic) induction followed a previously 
described protocol [23], where samples were cultured in VM for 8 days followed by 13 days 
of OM supplemented with VEGF and FGF-2. Vascular growth was assessed via 
immunostaining of fibrin gels (whole-mount) and PCL scaffolds (cryosections). Osteogenic 
differentiation in 3D samples was also assessed via immunostaining, as well as quantification 





Treatment with TNF and PDGF-BB 
 Different experimental models were employed in this study (Fig. 4.3). Initial 
experiments tested the effects of acute TNF exposure on osteogenesis and vascularization 
independently (Fig. 4.3A). ASCs were cultured in either OM (monolayer) or VM (fibrin gel), 
with the addition of TNF (0, 0.1, 1, 10, or 100 ng/mL) for the first 48 hours to mimic an 
acute inflammatory response. In the next experiment, the combined effects of TNF and 
PDGF-BB on dual (vascular and osteogenic) induction were assessed (Fig. 4.3B), as both 
factors are key mediators in the early bone-healing environment. Fibrin-encapsulated ASCs 
were treated with 0 or 20 ng/ml PDGF-BB (for the full 21 days of culture) and 0 or 0.1 
ng/ml TNF (for 2 or 21 days). To assess tissue development within implantable grafts, ASCs 
were seeded into PCL scaffolds and underwent vascular and osteogenic induction with the 
addition of 0 or 0.1 ng/ml TNF (for 2 days) and 20 ng/ml PDGF-BB (for 21 days), and 
either assessed at the end of in vitro culture (Fig. 4.3C) or implanted in vivo to assess the 
survival and integration of the grafts (Fig. 4.3D). 
 
 
Figure 4.3. Schematic of experimental approaches. (A) Osteogenic (monolayer) and vascular 
(aggregates in fibrin gel) cultures were studied separately in this experiment to study the effects of 
TNF dose (0 to 100 ng/ml for the first 2 days only) on each lineage. (B) Fibrin-encapsulated ASC 
aggregates underwent dual (vascular and osteogenic) induction using a step-wise approach [23]. The 
cells were treated with TNF and/or PDGF-BB to study their individual and combined effects. (C) 
ASC aggregates were seeded with fibrin gel into the pores of 3D-printed PCL scaffolds and induced 
to form vessels and mineral in order to study the spatial organization of tissue assembly within grafts. 
(D) These cultured grafts were implanted subcutaneously in athymic nude rats for 2 weeks to assess 





In Vivo Implantation 
 Male athymic nude rats (7 weeks old, n = 4 per group; Charles River Laboratories) were 
anesthetized with isofluorane. Two small incisions were made in the dorsal region of the skin 
to form bilateral subcutaneous pockets. One sample from each treatment group (± TNF) 
was placed in each rat (one sample per pocket), then the skin was sutured closed. All rats 
were sacrificed after 14 days for retrieval of scaffold implants, which were fixed in 3.7% 
formaldehyde at 4 ºC for 24 hours before histological analysis. 
 
Immunostaining and Histology 
 Fibrin gel samples were fixed in 3.7% formaldehyde at 4 ºC for 3 hours, followed by 
whole-mount immunostaining, which was performed as previously described [23]. Gels were 
mounted on glass slides and imaged using a Zeiss LSM 510 confocal microscope with a 5x 
objective. Fixed PCL scaffold samples were infiltrated with 30% sucrose, frozen in Tissue 
Tek OCT medium, and cut into 10 µm-thick sections. Cryosections were mounted and dried 
on Superfrost Plus slides, followed by rehydration in water before staining with either 
Hematoxylin and Eosin (H&E; Sigma) or immunohistochemistry. Immunohistochemistry 
was performed by blocking for 30 minutes (10% normal serum / 0.2% Triton X), followed 
by overnight incubation with primary antibodies at 4 ºC, 1-hour incubation with secondary 
antibodies at room temperature, and nuclear counterstain for 4’-6-diamidino-2-phenylindole 
(DAPI; Sigma). Cryosections were imaged using an inverted Zeiss Axio Observer 
microscope. Primary antibodies included: mouse anti-human CD31 (4 µg/mL, Sigma and 
Dako), Cy3-conjugated mouse anti-alpha smooth muscle actin (αSMA; 7 µg/ml, Sigma), 




Biotechnology), mouse anti-collagen I (1/1000, Abcam), goat anti-RUNX2 (4 µg/mL, Santa 
Cruz Biotechnology), and mouse anti-human Lamin A/C (0.5 µg/mL, Abcam). Secondary 
antibodies (Jackson ImmunoResearch) included: goat anti-mouse (DyLight 488) and goat 
anti-rabbit (DyLight 649) for in vitro samples; donkey anti-goat (AlexaFluor 488), donkey 
anti-mouse (Cy3), and donkey anti-rabbit (AlexaFluor 647) for in vivo samples. 
 
Image Analysis 
 Confocal z-stacks of immunostained gels were z-projected and thresholded for 
quantification of vessel network parameters (6 images per group). AngioQuant software [71] 
was used to quantify total vessel length and number of junctions (“interconnectivity”). 
Cryosectioned scaffold samples were analyzed with Image J software (NIH). A minimum of 
3 slices (spaced ≥ 100 µm apart) was analyzed from each independent sample. Nuclear 
counts (DAPI, RUNX-2, Lamin A/C) were performed with the Analyze Particles command 
on thresholded images and were normalized to the total graft area. Extracellular matrix 
deposition (“intensity”) was measured by taking the mean grey value of selected regions in 
non-thresholded images (entire graft region for Col-1 and OCN, and CD31+ overlay region 
for in vitro laminin). Percent vessel area (either CD31 for human vessels or laminin for rat 
and human vessels in vivo) was determined in cryosectioned samples by measuring the 
thresholded vessel area divided by the total graft area (mm2/mm2). 
 
Quantitative RT-PCR 
Total RNA was isolated using a TRIzol (Invitrogen) extraction method and quantified 




performed with 1 µg of total RNA using iScript cDNA Synthesis Kit (BioRAD). 
Complementary DNA was amplified using SYBR Green PCR Master Mix (Applied 
Biosystems) and a StepOnePlus Real-Time PCR System (Applied Biosystems). The primer 
sequences used for PCR analysis are listed in Table 2.1. Expression levels were calculated by 
the comparative CT method using GAPDH as an endogenous reference gene. 
 
Statistical Analysis 
 Statistical analyses were performed using GraphPad Prism 5 software. Quantitative data 
are expressed as mean ± standard error. An unpaired t-test was used for two-group 
comparisons. Multi-group comparisons were determined by either one-way ANOVA with 
Tukey’s post-test (for single factor studies) or two-way ANOVA with Bonferroni’s post-test 
(for multiple factor studies). Significance is denoted as *p < 0.05, **p < 0.01, ***p < 0.001. 
4.3 Results 
Cell Characterization 
 Passage 2 ASCs were predominantly positive for mesenchymal markers (97.2% CD73+, 
87.1% CD105+, and 99.2% PDGFR-β+), with very few cells positive for endothelial 
markers (0.64% CD31+ and 2.83% CD34+). All CD31+ cells were positive for PDGFR-β+. 
 
Effects of Acute TNF Exposure on Independent Lineage Induction 
 The addition of TNF to osteogenic cultures resulted in significantly greater calcium 
deposition, as shown by Alizarin Red S staining (Fig. 4.4A) and quantification of calcium 




to DNA content (to account for differences in cell number) was not different with any TNF 
dose (Fig. 4.4D). In vascular cultures (Fig. 4.4B), 0.1 ng/mL TNF significantly increased 
vascular network length (Fig. 4.4E) and interconnectivity (Fig. 4.4F). Higher doses showed 
no change (1 and 10 ng/mL) or significantly inhibited vascular growth (100 ng/mL). 
 
Figure 4.4. Effects of acute TNF exposure on independent lineage induction. ASCs were 
induced towards either osteogenic differentiation (2D monolayer) or vascular morphogenesis 
(spheroids in 3D fibrin gel) and treated with varying doses of exogenous TNF for the first 48 hours. 
Osteogenic cultures were assessed via Alizarin Red S stain for calcium deposits (A), as well as 
quantification of total calcium content (C) and calcium normalized to DNA content (D) (dotted line: 
non-osteogenic control). Vascular cultures were assessed via whole-mount immunostaining for CD31 
(green) and αSMA (red) (B), as well as quantification of vascular network length (E) and 
interconnectivity (F). Scale bars = 500 µm. Values shown as mean ± SEM. *p < 0.05, **p < 0.01, or 
***p < 0.001 versus 0 ng/ml TNF. 
 
Combined Effects of TNF and PDGF-BB on Dual Induction 
 Fibrin-encapsulated cell aggregates underwent vascular and osteogenic induction 




was enhanced after acute (2 days) TNF exposure (Fig. 4.5B-D), similar to the vascular-only 
cultures (Fig. 4.4B). However, chronic (21 days) exposure to the same concentration of 
TNF significantly reduced vascular growth, and was slightly inhibitory as compared to no 
TNF treatment. PDGF-BB significantly increased vascular growth in all groups, and 
demonstrated a synergistic increase in vessel interconnectivity in combination with TNF 
(interaction p-value = 0.0496). PDGF-BB also induced a significantly increase in 
osteogenesis (Fig. 4.5E-G), whereas TNF exposure did not elicit any significant differences, 
except for a reduction in osteocalcin staining with chronic (21 day) TNF exposure. 
 
Figure 4.5. Combined effects of TNF and PDGF-BB on vascular and osteogenic induction 
within fibrin gels. (A) Fibrin-encapsulated ASC aggregates underwent dual induction with the 
addition of TNF and/or PDGF-BB. (B) Whole-mount immunostaining for CD31 (green) and OCN 
(blue). Scale bar = 500 µm. Quantification of immunostains: (C) vascular network length, (D) 
vascular network interconnectivity, and (E) mean intensity of OCN deposits. (F) Total calcium 
content. (G) Calcium content normalized to DNA content. Values shown as mean ± SEM. 





Tissue Assembly in Composite Scaffolds 
 ASC aggregates seeded with fibrin gel into PCL scaffolds were evenly distributed 
throughout the pores at day 0 (Fig. 4.6A,B). After 21 days of vascular and osteogenic 
induction, new tissue formed more densely around the periphery of the scaffold, with no 
noticeable differences amongst treatment groups (Fig. 4.6C,D). Immunostaining for bone 
matrix proteins collagen I and osteocalcin was denser around the periphery of the scaffold, 
whereas most cells that stained positively for RUNX-2 (early osteogenic transcription factor) 
were located in the center (Fig. 4.6E,F). Quantification of these stains showed no statistical 
change as a result of TNF treatment (Fig. 4.6J). Staining for CD31 and laminin (vascular 
basement membrane) show vessels throughout the entire scaffold (Fig. 4.6G,H), with 
significantly greater vessel density (1.8-fold increase) and laminin intensity (1.5-fold increase) 
in scaffolds with acute TNF exposure (Fig. 4.6J). At the end of the 21-day induction period, 
endogenous VEGF-A expression was significantly higher after TNF treatment (Fig. 4.6I). 
 
In Vivo Integration of Vascularized Osteogenic Grafts 
 After 14 days in vivo, graft implants showed greater extracellular matrix production (Fig. 
4.7A,B) versus pre-implantation. The majority (55-65%) of cells within the grafts were 
positive for human-specific Lamin A/C (Fig. 4.7C,D), with no statistical difference in 
human cell density as a result of TNF exposure (Fig. 4.7I) nor when compared to the pre-
implantation density (Fig. 4.6J), indicating high cell retention. Staining for bone matrix 
proteins collagen I and osteocalcin was significantly greater and more uniformly distributed 
compared to pre-implantation (4-fold and 3-fold change, respectively) and also increased as a 




but significantly reduced compared to pre-implantation (0.5-fold change). Some human 
vessels remained viable within the grafts, although significantly less than what was implanted 
(0.2-fold change), with no significant difference amongst treatment groups (Fig. 4.7G,H,I). 
However, there was a dense host vessel infiltration in all grafts (indicated by laminin staining), 
with 1.5-fold greater total vascular area in the TNF-treated group versus control. 
 
Figure 4.6. Tissue assembly within PCL-fibrin composite scaffolds. ASC aggregates were 
seeded with fibrin gel into the open pores of PCL scaffolds. Initial cell distribution is shown via 
H&E staining of a cryosection (A) and whole-mount DAPI staining cross-sectional view (B) (PCL 
scaffold rods: ‘S’). Samples were induced to form vessels and mineral for 21 days with 20 ng/ml 
PDGF-BB and either no TNF (C,E,G) or 0.1 ng/ml TNF for 48 hours (D,F,H). Cryosections (10 
µm thick) were stained with H&E (C,D) or immunostained for osteogenic (E,F) and vascular (G,H) 
markers. Dotted lines indicate the scaffold rods and tissue boundary. Scale bars = 500 µm. (I) 
VEGF-A gene expression (dotted line indicates day 0). (J) Quantification of immunostaining. Values 






Figure 4.7. In vivo integration of vascularized osteogenic grafts. In vitro-induced grafts were 
implanted subcutaneously in athymic nude rats for 14 days. Staining of cryosections (10 µm thick): 
(A,B) H&E, (C,D) human-specific Lamin A/C (LMNA) to label implanted cells, (E,F) osteogenic 
markers, (G,H) vascular markers (human-specific CD31 and laminin (LAM) for rat/human vessels). 
Scale bars = 500 µm. (I) Quantification of immunostaining. Values shown as mean ± SEM. 
Significance indicated as **p < 0.01. 
4.4 Discussion 
 Bone is a resilient tissue that has the potential to fully heal itself after moderate injuries. 
When this happens, normal healing progresses towards full recovery through a tightly 
regulated cascade of inflammation, cellular and vascular recruitment, and a complex host of 
signaling molecules. However in the case of large, critical-sized defects, these normal healing 




confounding factors such as infection, mechanical instability, and absent sources of 
regenerative cues (i.e. periosteum, hematoma) [1, 134]. Historically, tissue engineers have 
vastly improved upon many of these shortcomings with the application of novel scaffolds, a 
variety of clinically relevant cells, and growth factors to instruct cells. More recently, 
inflammatory mediators have gained interest in the field because of their important roles in 
normal healing processes. The goal of this study was to study the effects of TNF, a key 
inflammatory cytokine, on vascular assembly and osteogenesis. We demonstrate that TNF 
acts synergistically with PDGF - another important component of the bone-healing cascade 
- to enhance vascularization within engineered osteogenic grafts. 
 Initial studies tested the effects of TNF dose on ASC osteogenesis and vascular 
morphogenesis in separate cultures, demonstrating that TNF has a beneficial effect on both 
lineages when supplied at a low dose for 48 hours. While TNF induced a moderate increase 
in mineralization, this was concomitant with an increase in DNA content, suggesting that the 
increased mineralization may be due to proliferation. However, previous studies have 
indicated that TNF induces increased endogenous production of bone morphogenetic 
protein-2 (BMP-2) in mesenchymal stem cells [128, 129], suggesting that there may be a 
direct osteogenic effect on the cells. Not all pro-inflammatory cytokines elicit the same 
response, as we conducted a similar experiment with interleukin-1β (IL-1β) that resulted in a 
significant increase in mineralization for all concentrations ranging from 0.1 – 100 ng/mL, 
but a sharp dose-dependent inhibition of vascular assembly. 
 In the in vitro model of vascularized bone development, acute (2-day) treatment with 
TNF increased vessel length and interconnectivity. However, continuous exposure to the 




supported by studies with endothelial cell cultures that have shown that continuous exposure 
to TNF can inhibit endothelial cell proliferation and growth factor responsiveness [121, 122]. 
In contrast to the monolayer osteogenesis experiment, mineralization was not significantly 
affected by the acute addition of TNF in the dual (vascular and osteogenic) induction model. 
This is likely due to the fact that TNF was only added during the vascular phase of culture 
(first two days). With the addition of PDGF, both vascularization and mineralization were 
improved, as was seen in our previous studies [23]. This PDGF-induced response was 
slightly synergistic in combination with the effects of TNF on the vascular development but 
not mineralization in these scaffolds. Ultimately, for in vivo applications, this improved 
vascular development is critical for graft survival and integration with host tissue.  
 Tissue development within composite fibrin-PCL scaffolds was studied before in vivo 
implantation because the spatial, mechanical, and biochemical transport properties are more 
complex than within a homogenous fibrin gel. Despite being uniformly seeded throughout 
the pores, the tissue formed more densely around the periphery of the scaffold (independent 
of TNF treatment) following three weeks of in vitro induction. This may be due to diffusion-
limited gradients of oxygen and nutrients [135], given that cells form a layer of dense tissue 
on the scaffold periphery that may significantly reduce oxygen transfer to the central regions. 
Another hypothesis regards the differential constraints on the gel, which may remain fairly 
soft in the center, while the fibrin fibers near the edges where the PCL rods terminate are 
free to contract inward and stiffen [136]. Increased mechanical stiffness may play a role in 
facilitating the osteogenic response of ASCs [137]. Another observation at this time-point 
was that the majority of the cells in the center of the scaffold expressed RUNX-2, an early 




differentiation. Vascular growth within the scaffolds was significantly improved after TNF 
treatment, and may be due to an increased endogenous VEGF-A expression. Interestingly, 
this increase in expression was detected at the end of the 3-week culture period, which was 
long after the TNF stimulus was removed, indicating a long-term effect on the cells. 
 After in vivo implantation, the pre-vascularized osteogenic grafts continued to mature, as 
indicated by the increase in H&E staining and greater deposition of collagen I and 
osteocalcin throughout the center of the graft. The decrease in RUNX-2+ cells (vs. pre-
implantation) may indicate progression to a more mature phenotype. Interestingly, almost all 
of the implanted human cells were retained after 2 weeks in vivo. However, the amount of 
human vessels decreased significantly after implantation, showing no difference in retention 
as a result of TNF treatment. Previous studies have indicated that pre-engineered vascular 
networks may lead to faster anastomosis and subsequent remodeling and replacement by 
host vessels, suggesting that persistence of implanted vessels may not be necessary for a 
positive outcome [138]. Interestingly, host vascular invasion in this study was greater in the 
TNF-treated grafts, which may be due to improved remodeling and replacement of human 
vascular networks and/or elevated endogenous expression levels of VEGF-A and MMP-9 
(data not shown), which are known to promote angiogenesis [139-141]. Therefore in the 
current study, acute TNF treatment had a greater long-term impact on vascularization. 
 An important consideration regarding these in vivo studies is the host inflammatory 
response. Nude Athymic rats were used for the animal model because they lack T-cells to 
enable xenograft implantation, but have normal B-cell and macrophage function [142]. In 
these animals, as well as immuno-competent animals or patients, there will undoubtedly be 




investigate the role of this response on the development and functional integration of 
vascularized osteogenic grafts. From a clinical standpoint, the in vivo inflammatory 
environment can change based on the nature of the defect (e.g. an inflamed, compound 
injury versus congenital defect), infection, and anti-inflammatory drugs that the patient may 
be taking. While chronic inflammation and recurring infection have been shown to delay or 
inhibit healing of large bone defects [143, 144], the use of anti-inflammatory drugs have also 
been shown to slow healing rates [145-147]. These considerations further highlight the need 
to understand the role of the in vivo inflammatory environment in functional bone repair. 
4.5 Conclusions 
In summary, this study demonstrates how the pro-inflammatory cytokine TNF impacts 
vascularization of osteogenic grafts with ASCs. We have shown that acute exposure to TNF 
significantly improves vascular network formation within these grafts while prolonged 
exposure abrogates this response. The addition of exogenous PDGF synergistically enhances 
vascular development and simultaneously enhances mineral deposition. While this study 
demonstrates one application of in vitro pre-engineering of these grafts, the findings may 
have broader significance i.e. the approach may be applied to in situ tissue development 
strategies by controlling the exogenous or endogenous release of TNF in vivo. Our study 
underscores that modulation of the inflammatory response may be a powerful strategy to 




Chapter 5  
Oxygen Is a Critical Determinant of 
Vascularization 
5.1 Introduction and Background 
Rapid vascularization is essential for the effective application of cell-based tissue 
engineering strategies, as cell survival is critically dependent on adequate supply of oxygen 
and nutrients. For example, it may take weeks for invading vasculature from the surrounding 
tissues to fully vascularize clinically sized, centimeter-scaled bone grafts. In the interim, 
diffusion of oxygen and nutrients into the center of the graft will be slow and countered by 
high consumption rates by the implanted cells, resulting in diffusion-limited oxygen 
gradients that can reach near anoxia within hours [148]. This ischemic environment is 
exacerbated if the surrounding tissue has incurred vascular damage due to trauma. 
Previous studies have demonstrated that vascularization and blood perfusion can be 
accelerated by stimulating endothelial cells (EC) within the graft to form a nascent vascular 
network that would be capable of anastomosing with host vessels in vivo [11-14]. Possible 
sources of autologous ECs include circulating endothelial progenitor cells and ECs derived 
from induced pluripotent stem cells [149-151]; however, their low yields necessitate 
extensive in vitro expansion. Adipose-derived stromal/stem cells (ASC) are an abundant, 




strategies that require stem cell differentiation or trophic signaling combined with vascular 
support. Our group has previously demonstrated that ASCs can self-assemble into 
interconnected, pericyte-stabilized vascular networks in fibrin gels in vitro [23]. These vessels 
assemble through EC proliferation and complex heterotypic signaling that is facilitated by 
aggregating the cells prior to encapsulation [23, 101]. 
Minimizing ex vivo manipulation and pre-cultivation of cells may be advantageous for 
clinical translation of cell-based tissue engineering approaches, which puts more emphasis on 
in situ tissue assembly and vascularization. However, there still remain several unknowns 
regarding the ability of ASCs to assemble into functional vascular networks within a 
metabolically challenging environment. Hypoxia is typically a potent stimulus for 
angiogenesis in vivo through increased expression of vascular endothelial growth factor 
(VEGF) by hypoxic cells [152]. ASCs similarly upregulate angiogenic factors in response to 
hypoxia [43, 52, 57, 153], which can promote EC survival and growth. However, when ECs 
themselves experience hypoxia, this can inhibit vascular assembly and stability [154] and 
induce apoptosis through increased production of reactive oxygen species [155, 156]. 
The current study aims to determine whether ASC-derived vessels can grow in hypoxia, 
and assesses the effects of vessel maturity (i.e. individual cells versus pre-formed vessels) on 
this hypoxic response. We demonstrate that there is a differential response to hypoxia 
depending on vessel maturity, which has important implications for vascularization strategies 
that utilize ASCs. 
5.2 Materials and Methods 




 Human subcutaneous adipose tissue was obtained in the form of lipoaspirate from 
female donors (n = 3) with written informed consent under the approval of the Johns 
Hopkins Medicine Institutional Review Board. ASCs were isolated as previously described 
[101]. Briefly, tissue was digested with collagenase (1 mg/mL; Worthington Biochemical 
Corp.) to isolate the stromal vascular fraction of cells. These cells were plated onto tissue 
culture plastic and were termed “passage 0 ASC” when they reached 80-90% confluence. 
ASCs were used at passage 2 for all experiments. Growth medium consisted of: high glucose 
DMEM (Gibco) with 10% fetal bovine serum (FBS; Atlanta Biologicals), 1% 
penicillin/streptomycin (Gibco), and 1 ng/mL basic fibroblast growth factor (FGF-2; 
PeproTech). All experiments were conducted with cells from three independent donors. 
 
Flow cytometry 
 Passage 2 ASCs were assessed via flow cytometry for surface expression of mesenchymal 
(CD73, CD105) and endothelial markers (CD31, CD34). Briefly, cells were suspended in 
phosphate buffered saline (PBS) containing 2% FBS and incubated with monoclonal 
antibodies for 30 min at 4 ºC. Cells were analyzed with a BD Accuri C6 flow cytometer. All 
antibodies were purchased from BD Biosciences. 
 
Cell aggregation via suspension culture 
 Cells were trypsinized and resuspended at a concentration of 250,000 cells/mL in growth 
medium containing 0.24% (w/v) methylcellulose (Sigma). The cell suspension was pipetted 




dish. After overnight suspension culture, cellular aggregates were collected with a pipet, and 
then centrifuged before encapsulation procedures. 
 
Aggregate encapsulation and culture 
 Cell aggregates were suspended in fibrinogen (8 mg/mL final; Sigma) and thrombin (2 
U/mL final; Sigma) at a final cell concentration of 2 x 104 cells/µL. Fibrin gels were formed 
by pipetting 12 µL of gel solution into 4-mm diameter wells and incubating at 37 ºC for 30 
min to allow complete gelation before adding medium. Each gel sample was fed with 1 mL 
of culture medium containing no added growth factors: Endothelial Basal Medium-2 (EBM-
2, Lonza), 10% FBS, and 1% penicillin/streptomycin. To assess de novo vascular assembly, 
freshly encapsulated cells were immediately cultured in either normoxia (20% O2) or hypoxia 
(2% or 0.2% O2) for 6 days with no media changes to allow for cell-driven nutrient depletion. 
To assess growth / stability of pre-formed vessels, encapsulated cells were first cultured in 
normoxia for 6 days with media changed every other day to establish vascular networks. At 
day 6, these samples were fed once more and then cultured in either normoxia or hypoxia 
for an additional 6 days with no media changes. Normoxic samples were maintained in a 37 
ºC incubator with 5% CO2, 95% ambient air. Hypoxic samples were placed in a modular 
incubator chamber (Billups-Rothenberg) that was flushed every other day with pre-mixed 
gas (0.2% or 2% O2 / 5% CO2 / N2 balance) and placed in a 37 ºC incubator. 
 
Viability and metabolism assessments 
 To assess cell viability, samples were incubated with LIVE/DEAD 




and imaged with a confocal microscope. Total DNA content was measured to gauge total 
cell number using the Quant-iT PicoGreen dsDNA Assay (Invitrogen) as previously 
described [101]. Glucose and lactate content in culture media were quantified using Glucose 
Assay Kit and L-Lactate Assay Kit I (Eton Bioscience) and subtracted from day 0 values to 
calculate consumption or production, respectively. These values were normalized to DNA 
content (pmol / cell). 
 
Enzyme-linked immunosorbent assay 
 To assess endogenous growth factor production, cells were cultured in 0.5 mL of serum-
free medium (EBM-2 + 1% penicillin/streptomycin) for 48 hours in either normoxia (20% 
O2) or hypoxia (0.2% or 2% O2). Supernatant was collected and assayed for VEGF and 
FGF-2 using human ELISA kits (PeproTech) according to the manufacturers protocol. Cells 
were also harvested and assayed for total DNA content to normalize growth factor 
production to cell number (ng / 106 cells). 
 
BrdU labeling 
 Cells were incubated with bromodeoxyuridine (BrdU, Sigma) to detect proliferating cells. 
Briefly, 10 µM BrdU was pipetted into existing culture medium (i.e. medium was not 
changed), and samples were quickly returned to their appropriate oxygen environment (less 
than 5 minutes of normoxic exposure) for a 20-hour incubation. Samples were then washed 







 Whole-mount immunostaining of fibrin gels was performed as previously described [23]. 
Briefly, samples were fixed with 3.7% formaldehyde for 3 hours at 4 ºC, washed with PBS, 
and blocked with 5% normal goat serum / 0.2% Triton X-100 / PBS for 3 hours at 4 ºC. 
Antibodies were incubated overnight at 4 ºC, followed by three 1-hour washes in PBS with 
0.1% Tween. Primary antibodies included: mouse anti-human CD31 (4 µg/mL, Sigma) and 
Cy3-conjugated mouse anti-alpha smooth muscle actin ( SMA; 7 µg/ml, Sigma). One 
secondary antibody was used: DyLight 488-conjugated goat anti-mouse (1:400, Jackson 
ImmunoResearch). 
Prior to staining for BrdU, samples were stained for all other antigens and post-fixed 
with 3.7% formaldehyde for 30 min to preserve the stain. Samples were then denatured with 
2N HCl / 0.5% Triton X-100 for 45 minutes at room temperature, washed, re-blocked, and 
then incubated with AlexaFluor 647-conjugated mouse anti-BrdU (4 µg/mL, Invitrogen) 
overnight at 4 ºC. Cell nuclei were counterstained with 4’-6-diamidino-2-phenylindole 
(DAPI; Sigma). 
 
Imaging and analysis 
 Immunostained gels were mounted on glass slides and imaged using a Zeiss LSM 510 
confocal microscope (5x and 20x objectives). Confocal z-stacks were z-projected and 
thresholded for quantification. AngioQuant software [71] was used to quantify total vessel 
length (sum of the lengths of all vessel branches within a gel). Image J software (NIH) was 
used for all other image analysis. Pericyte coverage was defined as αSMA+ area within at 




the CD31 channel of thresholded image composites. Selections were enlarged by 5 µm at all 
edges and applied to the αSMA channel. αSMA+ area fraction within the selected area was 
measured and displayed as “% Pericyte Coverage”. BrdU+ nuclei were counted with the 
Analyze Particles command. BrdU counts from the whole gel indicate overall proliferation 
within the culture (displayed as “Total # BrdU+”). To assess proliferation within the vessels 
only, CD31+ vessel area was selected and applied to the BrdU channel prior to counting 
within the selected area. This count was normalized to the CD31+ vessel area to account for 
differences in vessel density and is displayed as “# BrdU+ / CD31 (mm2)”. To approximate 
the survival / persistence of ECs within the culture, the total number of independent 
CD31+ units (ranging from solitary cells to small vessels) was counted and divided by the 




Total RNA was isolated using a TRIzol (Invitrogen) extraction method and 
quantified using a NanoDrop spectrophotometer (Thermo Scientific). Reverse transcription 
was performed with 1 µg of total RNA using iScript cDNA Synthesis Kit (BioRAD). 
Complementary DNA was amplified using SYBR Green PCR Master Mix (Applied 
Biosystems) and a StepOnePlus Real-Time PCR System (Applied Biosystems). Expression 
levels were calculated by the comparative CT method using β-Actin as an endogenous 
reference gene. Primers included: 





(ii) VEGF-A [RefSeq: NM_001025368] – sense: 5’-GCCTTGCCTTGCTGCTCTA-3', 
antisense: 5’-GATTCTGCCCTCCTCCTTCTG-3' 




 All experiments were conducted with cells from three independent donors (n = 3 
samples per donor). Quantitative data are expressed as mean ± standard error. Statistical 
analyses were performed using GraphPad Prism 5 software. Statistical significance was 
determined by one-way ANOVA with Tukey’s post-test and is denoted as *p < 0.05, **p < 
0.01, ***p < 0.001. 
5.3 Results 
Cell characterization 
 Passage 2 ASCs from multiple donors were predominantly positive for mesenchymal 
markers, CD73 (99.3 ± 0.2%), and CD105 (98.7 ± 0.5%), with very few cells positive for the 
mature endothelial marker CD31 (1.1 ± 0.1%) (Fig. 5.1A). Approximately half of the 
population expressed CD34 (46.9 ± 11%), which is expressed by native ASCs as well as 
endothelial progenitors. 
 
Spontaneous self-assembly of vessels 
Aggregated ASCs (Fig. 5.1B) spontaneously self-assembled into vascular networks in 6 




with cells from multiple donors (Fig. 5.1D). Vascular assembly still occurred even when 
medium was not replenished for the entire culture period, which sets the basis for the 
vascular assay in subsequent experiments. By only feeding at the start of culture, there will be 
cell-driven nutrient depletion and waste buildup to simulate the ischemic conditions that 
arise after in vivo implantation of avascular grafts. 
 
Figure 5.1. Cell characterization and spontaneous vascular assembly. (A) Flow cytometric 
analysis (average of three donors). (B) Morphology of cell aggregates immediately after fibrin 
encapsulation. (C) Vessels assembled within 6 days of culture in medium containing no added growth 
factors with routine (three) feedings or a single feeding at the onset of the culture. (D) Quantification 
of total vascular network length. Scale bars = 200 µm (B), 500 µm (C). 
 
Viability and growth factor production in hypoxia 
 ASCs cultured for 6 days in 0.2%, 2%, and 20% O2 all demonstrated high viability (Fig. 
5.2A) and similar DNA content (Fig. 5.2B). Endogenous secretion of the potent angiogenic 
growth factor VEGF was upregulated in hypoxia (Fig. 5.2C) relative to normoxic 
conditions, while another angiogenic growth factor, FGF-2, was down-regulated at 0.2% and 





Figure 5.2. ASC viability and growth factor production. ASCs were fed at day 0 and maintained 
in 0.2%, 2%, or 20% O2 for 6 days. (A) Live/Dead staining was used to assess viability at day 6. The 
number of viable (green) cells appeared similar in all groups. (B) The total DNA content normalized 
to day 0 was also similar in all groups. (C,D) VEGF and FGF2 production was assessed in all groups 
via ELISA after 48 hours in serum-free medium and normalized to DNA content. Scale bar = 500 
µm. Significance indicated versus normoxia (20% O2). 
 
De novo  vascular assembly is inhibited by hypoxia 
 To assess the effects of hypoxia/ischemia on de novo vascular assembly, freshly 
encapsulated cells were immediately transitioned into the 6-day hypoxia assay (Fig. 5.3A). 
Vascular assembly was substantially inhibited in both moderate (2% O2) and severe (0.2% 
O2) hypoxia (47% and 11% total vessel length versus normoxia, respectively) (Fig. 5.3B,F). 
Pericyte coverage of vessels was 3-fold less in hypoxia (Fig. 5.3C,G). Vessel proliferation 
was also significantly lower in hypoxia (Fig. 5.3H), even when normalized to vessel area 
(Fig. 5.3D). Interestingly, the majority of proliferating cells throughout the culture are 
vascular cells (Fig. 5.3I) (62%, 86%, and 90% of BrdU+ nuclei co-localize with CD31 in 
0.2%, 2%, and 20% O2, respectively), which corresponds to a similar reduction in 
proliferation within the total population (Fig. 5.3E). To approximate EC persistence within 
the cultures, we assessed the total number of spatially distinct CD31+ entities. These 
numbers were not significantly different in 0.2% or 2% O2 as compared to the number of 
CD31+ cells at day 0 (82.0% and 98.4% respectively) indicating that the majority of ECs 





Figure 5.3. Hypoxia inhibits de  novo  vascular assembly. (A) Experimental approach. Vascular 
length (B,F) and pericyte coverage (C,G) were significantly inhibited in hypoxic conditions versus 
20% O2. Proliferation (BrdU incorporation) was significantly reduced in hypoxia in vascular cells 
(D,H) and the entire population (E). Vascular cells constituted the majority of proliferating cells 
within the culture (I). Scale bars = 500 µm (F,I), 100 µm (G,H). Significance indicated vs. 20% O2. 
 
Pre-formed vessels grow more in hypoxia 
 To assess the effects of hypoxia on pre-formed vascular networks, ASCs were first 
allowed to self-assemble into a nascent vascular network for 6 days in normoxia with routine 
feedings before transitioning into the 6-day hypoxia assay (Fig. 5.4A). Contrary to the 





Figure 5.4. Moderate hypoxia enhances the growth and stability of pre-formed vessels. (A) 
Schematic of the experimental approach. (B,F) Vessels grew significantly longer in hypoxia by day 12 
versus day 6 (dotted line), with the greatest length in 2% O2. (C,G) Pericyte coverage decreased in all 
groups relative to day 6 (dotted line) but was highest in 2% O2. (D,E,H) Proliferation (BrdU 
incorporation) decreased in all groups relative to day 6 (dotted lines) but remained highest in the 2% 
O2 group. Scale bars = 500 µm (F), 100 µm (G,H). Significance indicated vs. 20% O2. 
 
hypoxia than normoxia (1.21, 1.56, and 1.01-fold increase in vascular length versus day 6 for 
0.2%, 2%, and 20% O2, respectively) (Fig. 5.4B,F). Vessels also became wider in 2% O2, 




(Fig. 5.4C,G) and cell proliferation (Fig. 5.4D,E,H) decreased in all groups after continued 
culture (versus day 6); however, they remained highest in 2% O2 and lowest in 0.2% O2. 
 
Figure 5.5. Comparison of ASC metabolic activity and gene expression immediate versus 
delayed hypoxia. Glucose consumption and lactate production increased in 0.2% and 2% O2 
relative to 20% O2 after 6 days of immediate hypoxia (de novo vascular assembly) (A) and delayed 
hypoxia (6 days of pre-culture in normoxia) (B). By day 12, continued normoxic culture resulted in 
reduced glucose and lactate metabolism versus day 6 (dotted lines), whereas hypoxic conditions 
increased glucose consumption. (C) mRNA expression of VEGF-A was substantially upregulated in 
hypoxia, with highest expression in 0.2% O2. VEGFR-2 expression was reduced in 2% O2, but 
unchanged in 0.2% O2 relative to normoxia. (D) Changes in VEGF-A and VEGFR-2 expression 
were even greater following delayed-onset hypoxia. Significance indicated versus normoxia (20% O2). 
 
Metabolism & gene expression 
 ASCs in hypoxia significantly increased glucose consumption and lactate production 
(Fig. 5.5A). When cells were pre-cultured in normoxia for 6 days before the onset of 
hypoxia, there was an even greater glycolytic increase in hypoxia relative to normoxia by day 
12 (Fig. 5.5B); however, basal levels of glucose consumption and lactate production were 
significantly lower after extended culture (2.9- and 1.6-fold decrease, respectively; day 12 vs. 
day 6). Expression of VEGF-A mRNA increased substantially after 6 days in hypoxia (Fig. 




days before hypoxia (Fig. 5.5D). VEGF receptor-2 (VEGFR-2) mRNA expression was 
lower in 2% O2, but similar in 0.2% O2 versus normoxia (Fig. 5.5C). Samples that were pre-
cultured before hypoxia demonstrated elevated VEGFR-2 expression at day 12 versus day 6 
(end of pre-culture) and the highest expression in 0.2% O2 (Fig. 5.5D). 
5.4 Discussion 
 Rapid vascularization is critical for the survival of cell-seeded tissue grafts after 
implantation, as inadequate diffusion of oxygen and nutrients may lead to cell death and 
tissue necrosis. ASCs, which exhibit spontaneous vascular self-assembly, may be a suitable 
cell population for providing tissue engineered grafts with an intrinsic vascular network [23].  
In this study, we tested whether this capacity for vascular assembly would be impacted by 
hypoxia, which might be expected following in vivo implantation into a defect site. We 
demonstrated that hypoxia severely inhibits de novo vascular assembly of ASCs, but promotes 
further growth of pre-formed vascular networks. 
 In this study, we removed all exogenously added growth factors (except for what may be 
in FBS) and demonstrated that ASCs are still able to rapidly and spontaneously assemble 
into vascular networks. This finding suggests that endogenous biochemical and physical 
signals may be instructing this cellular self-assembly. For example, ASCs express detectable 
levels of angiogenic growth factors VEGF and FGF-2 (1.81 and 1.35 ng / 106 cells / 2 days 
in normoxia, respectively). For this study, growing the cells without exogenous growth 
factors allows for a more direct assessment of cellular behavior in response to hypoxia. 
 In addition to low oxygen tension, transplanted cells will also experience cell-driven 




replicate this environment, cells were only fed at the start of the 6-day “simulated 
implantation” period during which oxygen tension was varied. A direct comparison of 
multiple media changes versus none shows that vessel network growth is slightly reduced 
but only significantly in one of the three tested donors. 
 Viability of ASCs remained high in all oxygen tensions, with no significant difference in 
cell number even in 0.2% oxygen. The cells may have compensated for reduced oxygen 
availability by shifting their metabolism more towards anaerobic glycolysis, as glucose 
consumption and lactate production were both significantly higher in hypoxia. Similar 
hypoxic resiliency and metabolic shifts have been demonstrated in ASCs [157] and other cell 
types [158, 159]. This finding is promising regarding the ability of ASCs to endure harsh 
ischemic environments after transplantation. 
Hypoxic ASCs increased endogenous expression of the potent angiogenic factor VEGF. 
This is in agreement with previous reports that ASCs increase angiogenic factor production 
in hypoxia [43, 52, 57, 153]. Interestingly, expression of another important angiogenic factor, 
FGF-2, was reduced in hypoxia. Despite the high overall viability and increased VEGF 
expression, de novo vascular assembly of ASCs was substantially inhibited in hypoxia. This 
finding is likely due to reduced proliferation of ECs, as BrdU incorporation was significantly 
reduced within vessels. Substantial apoptosis is unlikely, as the total number of independent 
vessel structures (often individual cells in 0.2% O2 and small vessels in 2% O2; Fig. 3F) was 
not significantly reduced when compared to the number of ECs encapsulated at day 0. This 
metric of counting vessels and cells alike as just one cell is based on our earlier studies that 
demonstrated that each vessel arises from an individual EC [101]. Pericyte coverage was 




monolayer ASC cultures [101]. Those monolayer experiments, however, demonstrated no 
significant change in vessel length when grown in hypoxia, which is an interesting 
observation that warrants further investigation. 
Hypoxia is a potent stimulus for angiogenesis in vivo, inducing increased VEGF 
expression that recruits the sprouting and growth of pre-formed vessels. Angiogenic vessels 
may not experience severe hypoxia themselves, as they are constantly near a source of blood, 
only responding to indirect indicators of hypoxic stress. The de novo vascular assembly model 
presented in this study is fundamentally different from angiogenic sprouting in a number of 
ways, including the fact that the ECs are immature and are not a part of a vessel when the 
metabolic insult begins. Therefore, we assessed the effects of hypoxia on vessels that were 
first grown in a normoxic environment with routine media changes to establish healthy 
vascular network structures. Surprisingly, hypoxia induced increased vascular growth versus 
normoxia when vessels were pre-formed. By day 12, vessels demonstrated maximal growth, 
proliferation, and pericyte coverage in 2% O2. While the vascular networks in 0.2% O2 also 
increased in length, endothelial morphology indicated destabilization of the vascular 
structure. This observation may be due to the 36-fold increase in endogenous VEGF-A 
expression, which can cause pericyte detachment and loosening of EC junctions to prime 
vessels for sprouting [160]. 
The results of these experiments indicate a differential response of ECs within ASC 
cultures towards hypoxia depending on whether they are individual cells or incorporated into 
a pericyte-stabilized tissue structure. Despite similar global changes in metabolism and 
growth factor expression in each experimental approach, there were marked differences in 




role in this complex system. Pericyte investment promotes EC survival through the 
expression of VEGF-A and anti-apoptotic factors [161]. Interestingly, the extended culture 
period experienced by the pre-formed vessels resulted in decreased glycolytic activity and 
proliferation, but increased expression of VEGF-A and VEGFR-2 versus earlier timepoints. 
It is possible that the early phase of de novo vascular assembly requires higher proliferation 
and metabolic activity in order to initiate the nascent vascular plexus, and is therefore 
dramatically inhibited when the oxygen tension is reduced. 
The findings of this study have important implications on vascularization strategies for 
tissue engineering. Immediate encapsulation and implantation of ASCs into hypoxic tissues 
may impair their ability to assemble into functional vascular networks. However, delaying 
this exposure to hypoxia may result in improved vascularization. This may be achieved by 
pre-assembly of vascular networks prior to implantation or through oxygen delivery 
strategies in situ [162-164]. The in vivo tissue environment is certainly much more complex, 
with inflammation, cellular invasion, and other biological signaling occurring after 
implantation of a cell-seeded graft.  On-going in vivo studies are necessary to completely 
understand the impact of this complex post-implantation environment on the ability of 
ASCs to functionally vascularize a graft in situ. 
5.5 Conclusions 
 This study reveals striking phenomena and provides important insights into the 
differential responses of ASC-derived vessels to hypoxia. ASCs are a heterogeneous 
population of stem cells. Sub-populations of ECs and pericytes present within the ASCs can 




system is remarkably sensitive to changes in oxygen levels. Depending on the stage of tissue 
assembly and maturity, hypoxia may have disparate effects. We demonstrated that moderate 
hypoxia has a negative impact on de novo vascular assembly but positively impacts the stability 
and growth of pre-formed vessels.  These novel findings are of importance to the tissue 





Chapter 6  
Conclusions and Future Perspectives 
The data presented here demonstrate the ability of a heterogeneous cell source to build a 
complex tissue through endogenous self-assembly mechanisms and exogenously controlled 
biochemical environments. This final chapter summarizes the most important conclusions, 
contributions, and future research directions that have resulted from this work. 
6.1 Conclusions and Contributions 
Aim 1 Conclusions 
Chapter 2 describes the ability of ASCs to spontaneously self-assemble into three-
dimensional (3D) vascular networks. These surprisingly mature vessels displayed classic 
morphology: patent lumens, sprouting endothelial tip cells, invested pericytes, and vascular 
basement membrane. Observations from a detailed time course study and a serial passaging 
experiment revealed that these complex vessels originated from existing sub-populations 
(<1%) of endothelial cells and pericytes that were likely derived from the adipose tissue 
microvasculature and diminish in vitro through continuous passaging. Vascular growth 
required extensive endothelial proliferation and was facilitated by increasing direct cell-cell 
contacts (e.g. high cell density in monolayer and spheroid aggregation in 3D gel culture). 
Pericyte recruitment was mediated by PDGF receptor signaling. 
This chapter established a 3D vascularization model: ASCs were aggregated into 




in medium containing angiogenic growth factors. This experimental model yields highly 
interconnected vascular networks, setting the foundation upon which the remainder of this 
thesis was built. The body of work described in this aim resulted in one journal publication 
(featured on the cover), six conference abstracts, and a pre-doctoral fellowship application 
(successfully funded). 
 
Aim 2 Conclusions 
The body of work that spans Chapters 3 and 4 established an in vitro model to induce 
vascularized bone development by recapitulating key factors that initiate native bone repair. 
It was first demonstrated that the classic inductive factors in osteogenic medium are 
inhibitory to ASC vascular assembly. This necessitated the development of a step-wise 
approach in which vessels are allowed to grow and stabilize for one week in purely vascular 
medium before osteogenic factors are added. While this approach mitigated the initial 
inhibition of growth, vessel stability in the presence of osteogenic factors was poor, leading 
to gradual regression. After extensive literature review, key factors were identified that 
initiate angiogenesis and osteoprogenitor recruitment / activation in native bone injury: 
PDGF (released by activated platelets) and pro-inflammatory cytokines (released by activated 
macrophages; eventually narrowed down to TNF). Each of these factors was studied in great 
detail, looking at their effects on osteogenesis and vascular assembly separately and in the 
vascularized bone model. 
Chapter 3 describes the unique ability of a single growth factor, PDGF-BB, to 
substantially increase both osteogenesis and vascular stability, resulting in greatly improved 




improved upon this model by demonstrating that acute (48-hour) exposure to TNF 
significantly improves vascular assembly in vascularized bone grafts, and provides synergistic 
improvement when combined with PDGF-BB. These pre-engineered vascularized bone 
grafts were tested in vivo in a subcutaneous model. Bone matrix continued to mature in vivo, 
and was combined with extensive host angiogenic ingrowth. However, engineered vessels 
became less dense, either because of regression or remodeling by the host. 
This aim illustrated several important points: (i) ASCs are capable of forming vessels and 
mineralized matrix in the same tissue construct, (ii) a biomimetic approach towards 
vascularized bone engineering yields improved development of complex tissue structures, 
(iii) additional unknowns remain regarding how the in vivo environment will impact ASC 
vascularization. This body of work resulted in five journal publications (one featured on the 
cover), seven conference abstracts, and one provisional patent. 
 
Aim 3 Conclusions 
Chapter 5 demonstrated that oxygen tension is a critical determinant of ASC vascular 
morphogenesis. This topic was of great interest given the ischemic environment that cells 
would face in a large bone defect environment. Initial experiments demonstrated high cell 
viability and increased endogenous production of VEGF in hypoxia. However, the major 
finding was that hypoxia severely inhibits de novo vascular assembly, but promotes growth 
and stability when the onset of hypoxia is delayed until after vessels have assembled. This 
finding correlated with changes in endothelial proliferation, suggesting that hypoxia 
differentially impacts endothelial growth depending on the maturity of the tissue. The 




have important implications for the vascular tissue engineering field as a whole. This work 
resulted in one journal publication and one conference abstract. 
6.2 Future Perspectives 
This dissertation established feasibility for the use of ASCs to engineer vascularized bone 
and identified numerous factors that guide the cells towards more robust tissue formation. 
The majority of the work was conducted in vitro, which allowed for a controlled 
microenvironment in which to study cellular behavior. However, in vivo studies are the 
necessary next step to understand the real therapeutic potential of this approach, as the 
complexity and dynamics of in vivo environments will undoubtedly affect cellular behavior. 
Additionally, the development of a clinically translatable approach will likely require reduced 
ex vivo manipulation and pre-cultivation of cells, working towards the ideal of achieving 
complete tissue assembly from freshly implanted cells within the defect site (i.e. in situ). 
 An important question that arises when moving from in vitro to in vivo is – “How much 
of what we have learned holds true in vivo?” An essential study will be to assess the dynamics 
of ASC vascular morphogenesis in vivo within a bone defect. As was demonstrated in 
Chapters 4 and 5, ASC vascular assembly is drastically impacted by inflammatory cytokines 
and changes in oxygen tension. Therefore, the complexity and dynamics of the innate 
immune response and local ischemia within a bone defect will have an impact that is not yet 
known. Depending on the nature of the study, it may be advantageous to utilize autologous 
or syngeneic ASC sources within an immunocompetent animal model (e.g. mouse ASC into 





  Modulating the bone defect microenvironment through controlled release of factors or 
biomaterial modifications may allow for tighter control of cellular responses. For example, a 
study could expand upon the findings in Chapter 3 to understand how exogenous PDGF-
BB impacts ASC vascularization and osteogenesis in vivo. This study would be fundamentally 
different from my existing work because bone provides a more complex osteoinductive 
environment than the factors provided in vitro.  
The insights gained in Chapter 5 illustrate the need to tune the oxygen environment in 
order to maximize ASC vascular assembly and growth. ASCs placed in an ischemic 
environment and/or a very large, densely seeded scaffold will rapidly experience hypoxia. 
This scenario resulted in poor vascular assembly in my in vitro studies. As discussed in 
Chapter 5, methods to delay the onset of hypoxia may greatly improve the ability of vessels 
to pre-form and become stabilized. Therefore, future studies could address this challenge by 
locally producing / delivering oxygen from the scaffold through chemical [162-164] or 
physical means [unpublished method from our lab]. 
Clinical adoption of cell therapies for tissue regeneration has been limited by challenges 
such as safety, efficacy, reproducibility, and cost. Currently, intraoperative procedures appear 
be the most viable option to lower these hurdles by minimizing ex vivo manipulation and 
culture of cells. This means that the cells would be isolated, processed, and transplanted back 
in vivo without leaving the operating room. Therefore, freshly isolated SVF may be more 
translatable than cultured ASCs. Uncultured SVF contains at least 10-fold greater endothelial 
population than what was used in my studies, which may result in improved vascularization 
potential. Additional studies are required to assess the vascular and osteogenic properties of 




Appendix: Supplementary Protocols 
A1. Isolation of Adipose-Derived Stem Cells 
1. Transfer lipoaspirate into multiple 50 ml tubes (up to 20 ml / tube). Add an equal 
volume of warm collagenase solution (1 mg/mL Collagenase Type I + 10 mg/mL 
bovine serum albumin + PBS with Ca2+). Shake tube to mix well. 
2. Place all tubes on an orbital shaker (laying sideways for ample agitation) inside a 37ºC 
incubator for 1 hour or until the tissue appears smooth. 
3. Centrifuge the tubes at 300 g for 5 min. Shake the tubes to disrupt the cell pellet. 
Centrifuge again at 300 g for 5 min (dislodges residual adipocytes from pellet). 
4. Using a serological pipet, carefully remove the top (oil / fatty tissue) and middle 
(mostly collagenase) layers, and discard into a waste bottle. Leave the bottom ~5mL 
to avoid disrupting the SVF pellet. 
5. Resuspend the pellet with ~20 mL of PBS. Pass the cell suspension through a 100-
µm cell strainer. Collect in fresh 50 ml tubes. Bring volume up to 50 mL with PBS. 
Centrifuge at 300 g for 5 min. Remove all oil and PBS with a pipet. 
6. Resuspend pellet in 10 - 20 ml of 1X RBC lysis buffer. Incubate 7 min. Pour PBS 
into the tubes to dilute the buffer, then centrifuge at 300 g for 5 min. 
7. Resuspend the cell pellet in 10 ml of medium. Count cells. 
8. Split cells into the appropriate number of flasks (T-175 flask: ~ 33 ml of lipoaspirate 
tissue or 10 - 15 x 106 cells). Culture in high glucose DMEM + 10% FBS + 1% 




A2. Cell Aggregation in Suspension Culture 
1. Prepare a 1.2% (w/v) methylcellulose stock solution in basal medium. Advanced 
preparation requires autoclaving the powder and overnight mixing steps [165]. 
2. Dilute methylcellulose 1:5 in culture medium. Warm to 37ºC. 
3. Coat 10-cm petri dishes (non-TC-treated is fine) with 6 mL of sterile 2% agarose. 
While still liquid, swirl the dishes to evenly distribute the agarose. Set at room 
temperature for 10 min, followed by 10 min at 4ºC. Add 6 mL of basal medium to 
each dish. Equilibrate at 37ºC for at least 30 min. Carefully aspirate the DMEM from 
each dish prior to adding cells. 
4. Suspend trypsinized cells to 250,000 cells/mL in methylcellulose working solution. 
Pipet 5 – 6 mL of cell suspension into each dish (1.25 – 1.5 x 106 cells/dish). 
5. Transfer dishes to 37ºC incubator overnight (~15-20 hours). Do not stack more than 
2 dishes together. Taller stacks result in larger, more heterogeneously sized clusters. 
A3. Preparation of PDMS Molds for Casting Gels 
1. Obtain Polydimethylsiloxane (PDMS) – Dow Corning Sylgard 184 kit 
2. Mix the PDMS base and curing agent at a 10:1 ratio (w/w). Weigh in a medium-sized 
disposable weigh boat. Stir well with a disposable spatula. 
3. Remove air bubbles by placing the mixed solution in a vacuum desiccator for 10 min. 
4. Pour the PDMS solution into a mold to cast a flat sheet (e.g. large-sized disposable 
weigh boat). Note that the quantity of PDMS solution and the geometry of the mold 
will determine the thickness of the resulting sheet. Optimize according to the desired 




5. Incubate at 80ºC for 20-60 min or until fully solidified. 
6. Remove the solid PDMS sheet from the mold. Punch custom cylindrical molds using 
biopsy punches (e.g. a ring shape with 6 mm I.D. and 12 mm O.D.). The inner 
diameter represents the size of the hydrogel. 
7. Autoclave molds to sterilize. Place molds in tissue culture multi-well plates using 
sterile forceps. Clean PDMS (i.e. no dust) should stick / bond completely to the 
plate such that liquid cannot pass underneath. 
A4. Cell Encapsulation in Fibrin Gels 
1. Prepare 10 mg/mL fibrinogen in PBS without Ca2+. Sterile filter prior to use. Store at 
4ºC and use within 1 day. Prepare 10 U/mL thrombin in PBS with Ca2+ from sterile 
stocks. Make fresh each day. 
2. Suspend cells in fibrinogen at 25% greater concentration than desired to account for 
the addition of thrombin. Aliquot the suspension into multiple 0.5 mL tubes with 
each containing enough volume for only 3 gels (e.g. 92 µL of fibrinogen for 3 x 35 
µL fibrin gels) because gelation will be fairly rapid (< 1 min) after thrombin is added. 
3. To each aliquot of fibrinogen + cells, add thrombin at a 1:4 ratio. Final 
concentrations should be 8 mg/mL fibrinogen and 2 U/mL thrombin. 
4. Mix well and pipet 3 gel volumes into PDMS molds (e.g. 15 µL into 4 mm I.D. or 35 
µL into 6 mm I.D. results in a gel with 1 mm thickness). Change pipet tips and 
repeat for each aliquot. 
5. Incubate for 30 min at 37ºC for complete gelation before adding medium to the well. 




A5. Whole-Mount Immunostaining 
1. Technical Notes: All steps occur at 4ºC on a rocker. Transfer samples into 2 mL 
round-bottom tubes for improved agitation. Biological replicates can be combined 
into the same tube. Keep tubes upright at ~125 rpm during small-volume incubation 
steps and side-ways at ~75 rpm during large-volume wash steps. All wash steps are 
in 1.5 mL of 0.1% Tween-20 in PBS (PTw). Antibodies are diluted in 5% normal 
serum in PTw and utilize a minimal volume to cover the samples (e.g. 100 µL). 
2. Gently release the gels from their PDMS molds by cutting the edges of the gel with 
an equal-sized biopsy punch. Transfer gels to 2 mL tubes. 
3. Block and permeabilize in 5% normal serum + 0.2% Triton X + PBS for 2+ hours 
4. Incubate with primary antibodies overnight. Wash 3 x 1 hour. 
5. Incubate with secondary antibodies for overnight (can be shortened to several hours 
at room temperature, but may increase background). Wash 3 x 1 hour. 
6. Note: Co-staining with two mouse primaries (e.g. CD31 and αSMA) must be done 
sequentially. Follow the complete staining protocol (through Step 5) for the 
unconjugated primary, then re-block with mouse serum for 1 hour before incubating 
with the conjugated primary overnight. This lengthens the entire process by 1 day. 
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